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ABSTRACT
The field of bone tissue engineering features a wide variety of biomaterials
designed to facilitate repair and restoration of injured bone tissue. Due to the
complex nature of bone, these graft materials face unique challenges in
accommodating this highly dynamic environment in which internal structures are
being constantly remodeled via osteoblastic and osteoclastic functions. Therefore,
effective graft designs must incorporate compositional elements that are capable
of promoting and facilitating such activity to permit successful integration with
native tissue. These osteobiologic characteristics, including osteo-conduction,
osteo-induction, and osseo-integration, are key factors in determining a materials
osteogenic capacity and its potential as a bone graft technology. The comprised
studies focus on the development and biological assessment of a construct that
incorporates osteobiologic components, nano-hydroxyapatite (nHA) and
decellularized bone particles (DBPs), within a polymeric binder to form osteogenic
matrices for enhancing bone repair. A battery of in vitro and in vivo assessments
of this osteogenic platform were carried out at various stages of the development
process to characterize the impact of this biomaterial on multiple cell lines, both
immortalized and naïve, as well as in different rodent bone defect models, in both
long bone and oromaxillofacial applications. Promising in vitro and in vivo data at
early stages paved the way for more extensive testing, in particular the
examination of target proteins expressed in treated tissue, through
immunohistochemical techniques, and of the molecular impact of the graft
material, using both metabolomic and transcriptomics. Positive detection of key
proteins associated with osteogenic and cell attachment functions further
supported evidence that scaffolds served as effective matrices for cellular
migration and subsequent osteo-differentiation. Additionally, the development of
potential pathways of effect for these constructs on exposed naïve cells provided
key targets for future studies, which may elucidate the precise mechanisms
responsible for the observed biological responses. Furthermore, this multi-omics
methodology presents a powerful tool for the evaluation of new graft technologies,
promoting the potential of intelligent biomaterial design for specific applications.
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CHAPTER I:
INTRODUCTION TO OSTEOBIOLOGICS

1

A version of this chapter was originally published by Austin J. Bow:
Bow, A., Anderson, D. E., & Dhar, M. (2019). Commercially available bone graft
substitutes: the impact of origin and processing on graft functionality. Drug
Metabolism Reviews, 1-12. doi:10.1080/03602532.2019.1671860
This is an article published by Taylor & Francis in a special issue of the
Journal
of
Drug
Metabolism
Reviews
October
2019,
available
online: https://doi.org/10.1080/03602532.2019.1671860. Copyrights have been
obtained for using content from this originally published work in the following
chapter.

A Brief Introduction to Bone
Far from the static structure that it is sometimes portrayed, bone comprises
of a highly dynamic system regularly undergoing remodeling based on skeletal
force distribution. This process relies on specialized cells, namely osteoclasts and
osteoblasts, capable of resorbing existing substrate and depositing new bone
respectively. Osteoclasts, which are multinucleated cell bodies formed from
hematopoietic precursors of monocytic and macrophagic lineage, operate to
degrade existing structures enzymatically exposing mature osteocytes embedded
within matrix (Lemma et al., 2016). Osteoblasts, which form epithelioid structures
along the surface of existing bone, modulate secretion of bone organic matrix and
mineralization at this interface (Blair et al., 2017). During this deposition process,
osteoblasts become encased within the newly formed mineral construct and
mature to osteocytes, which comprise over 90% of the cellular content of bone and
has demonstrated the ability to regulate the balance between remodeling agents
(Bellido, 2014; Hasan et al., 2018). The operation and coordination of function for
these critical structural remodeling agents is heavily reliant on the flux of chemical
signals produced by the extracellular matrix (ECM) in the form of proteins and
growth factors, which stimulate highly specific reactionary cascades. These
signaling cascades are largely responsible for the recruitment and differentiation
of precursor cells through-out the repair process (Majidinia et al., 2018).
The complex interaction of the described mechanisms can be credited for
the impressive regenerative capacity of bone, with functional repair and restoration
possible for even large tissue trauma. However, for injuries that exceed the
healing capabilities of the tissue, what is known as a critically-sized defect,
spontaneous regeneration and repair will not be possible. It is therefore necessary
for such cases to implement a graft material to facilitate cellular migration and
signaling through the defect region permitting effective repair (Noori et al., 2017).
For this reason, the development of effective bone graft materials has been a major
research focus, resulting in a wide range of scaffold designs with varying
advantages and disadvantages.
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Osteobiologic Products
In designing an optimal graft material for bone tissue engineering
applications, the product should display key osteobiologic characteristics (Cornell,
2004), such as osteo-conductive, osteo-inductive, and osseo-integrative attributes,
to be capable of facilitating and promoting growth of new bone tissue, as well as
integration with native tissue. Biomaterials that mimic or utilize the natural
architecture of bone therefore offer superior function for not only encouraging the
migration of local progenitor cells, but also to serve as a substrate for tissue
development.
Additionally, the combination of micro- and nano-scale
topographical elements have been observed to significantly impact the interaction
with and activity of exposed cells (Zhu et al., 2017; Jackson et al., 2018). The
current gold standard for grafting material is the use of autologous bone, tissue
harvested from a donor site of the individual receiving the graft, as this does not
pose concerns of immune response or disease transmission while presenting an
optimal construct for tissue in-growth (Azi et al., 2016). However, autologous
grafts are limited with respect to available source material and raise concerns of
donor site morbidity (Lee et al., 2018). For this reason, the use of allogenic,
xenogeneic, and synthetic graft materials offer attractive alternatives with regard
to availability and cost parameters. Furthermore, the application of bioactive
agents such as proteins and growth factors closely associated with osteogenesis
or genetic manipulation through both viral and non-viral methods have
demonstrated the potential to enhance existing scaffold technologies, as well as
act as effective stand-alone treatments (Hasan et al., 2018).
This section will explore commonly employed, commercially available bone
graft and bioactive materials of both organic and synthetic origin found through a
rudimentary web-based search of PubMed and Medline databases. The examined
materials, assessed based on origin and matrix composition, will be separated into
allogenic, xenogeneic, synthetic, and bioactive graft classifications. Evaluation of
the advantages and disadvantages associated with each graft type will be driven
by comparison of material processing methods and tissue interaction postimplantation. The application of explored commercially available materials in
combination with experimental elements, such as cell-based delivery platforms or
polymer binder additions, will not be addressed further in this article (Rao and
Stegemann, 2013; Lei et al., 2018).
Allograft Products
Allografts comprise of scaffolds and particles derived from human cadavers,
thereby maintaining architecture and extracellular proteins identical to that
observed in the native bone tissue. For this reason, this category of grafting
material demonstrates strong osteoconductive and integrative capabilities, as well
as varying degrees of osteo-inductive potential based on the processing method
utilized (Drosos et al., 2015; Kadam et al., 2016). The primary concern with
allografts is the risk of disease transmission or immune response due to same
3

species transplantation. To address this, the harvested samples are most
commonly subjected to a freeze-drying procedure to eliminate the cellular
component of the tissue. Removal of this element permits a drastic reduction in
the risk factors associated with allografts. The remaining extracellular matrix can
then be applied as a scaffold material or reduced to particles of specific size ranges
for void filling applications. By varying the duration and number of freeze-dry
cycles, the resulting scaffold can have significantly altered mechanical stability and
surface protein characteristics (Kadam et al., 2016), making it suitable for new
bone repair and regeneration
Further processing of harvested human allograft bone can be conducted
using an acid extraction to produce demineralized bone matrix (DBM), the general
process of which can be observed in Figure 1.1. DBM is comprised of the organic
elements of the bone, including proteins and other growth factors, which maintain
the osteoconductive and osteo-inductive characteristics while removing the
mineral structural components of the matrix. This permits the product to be
implemented in a variety of means including granular particles, powders, or putties
for filling void spaces (Kadam et al., 2016). Additionally, the process of
demineralization reduces antigenic structures that may cause an immunological
response, though this will still vary depending on the extent of the demineralization
(Drosos et al., 2015).
Commonly used and characterized commercially available allograft
materials include both freeze-dried and DBM products, as well as different material
forms for some products. [The products: Grafton®, MinerOss®, RaptOs®,
Cancellous Chips, Puros®, and RegenerOss®, were selected though a basic webbased search of commonly implemented allogenic grafts.]
Grafton® DBM (BioHorizons)
Grafton® DBM is an allogenic graft material produced and distributed by
BioHorizons that provides a scaffold matrix encompassing both osteoconductive
and osteo-inductive properties. As noted in Kadam et al. (2016), Grafton® DBM
has been implemented in a wide variety of applications including sclerosis, cervical
spine, and lumbar fusion applications. It is intended to be applied as in cases
requiring bone graft extensions, substitute, or filler that are not directly related to
structural stability or weightbearing sites. This is due to the DBM grafts maintaining
low mechanical strength as compared to the compression forces observed in
weightbearing skeletal structures. For this reason, a particularly attractive
application of Grafton® DBM is in oromaxillofacial surgical applications, such as in
alveolar ridge augmentation. The graft material is designed to be absorbed and
replaced by native tissue during normal remodeling of the defect region. A
prospective randomized clinical trial comparing Grafton® DBM with an autologous
graft material harvested from the iliac crest bone (ICBG) was conducted to
determine efficiency in fusion with local bone. The study conducted by Kang et al.
(2012), assessed the 2-year follow-up of 41 patients that had received either the
Grafton® DBM (n=28) or ICBG (n=13) for final fusion rates. There was no
4

significant difference between the two groups (Kang et al., 2012), Indicating that
the Grafton® DBM material may be capable of facilitating comparable repair to
autogenic graft materials for bone injuries where fusion is required.
MinerOss® Chips (BioHorizons)
MinerOss® particles are an allogenic graft product produced and distributed
by BioHorizons that are derived from either cortical bone, cancellous bone, or a
blend. The freeze-dry process used for this product results in a mineralized
particulate material with both strong osteoconductive properties and enhanced
surface area for tissue interaction. These particle materials (particle size ranging
from 600μm to 1250 μm) are intended, as per the product page, for implementation
as a defect filler in ridge/sinus augmentation and socket grafting to act as a mineral
matrix for native tissue in-growth. A study was conducted to assess MinerOss®
particles as a primary grafting material for a sinus augmentation procedure and
was followed for a post-operative period of 6 months. Bone core biopsies
harvested during implant placement permitted histological evaluation of grafttissue integration. Implants placed in graft-filled defects (n=39) demonstrated
satisfactory stability, with only one implant failing, and histologic analysis revealed
strong osseo-integration characteristics (Avila et al., 2010).
RaptOs® (Citagenix)
RaptOs® is an allogenic graft block product produced and distributed by
Citagenix derived from cortico-cancellous bone. As per product page, the graft
material is intended for filling bony void space in non-weightbearing osseous
defects, since compressive mechanical forces of skeletal bone exceed those
observed in allogenic products produced through freeze-dry processes. In a study
conducted by Kaya et al. (2015), RaptOs® was evaluated histologically for bone
reparative characteristics in a tibial defect model alongside two other graft
materials of different origins, BioOss® (xenogeneic) and β-tricalcium phosphate
(synthetic). Generated in both tibias of 28 Wistar rats, the defects measured 10mm
in length, 3mm in depth, and 2mm in width. Each rat was one of the three grafts
in both legs, or left void for control samples, with one site receiving a pretreatment
with a commonly employed antibiotic, rifampin. 21 days post-operatively rats were
sacrificed, and samples were harvested for histological sectioning. Defects treated
with RaptOs®, without inclusion of the antibiotic, demonstrated partial unions and
early stage development of woven bone, as indicated by the presence of collagen
fibers within the site. Despite the low cellular activity observed, these samples did
maintain a consistently higher degree of cell activity as compared to the unfilled
control samples and displayed the presence of bone marrow along the periphery
of the material (Kaya et al., 2015). This study indicated that the human allograft
product was capable of acting as a supplemental matrix within the defects to permit
early-stage repair.
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Cancellous Chips (Musculoskeletal Transplant Foundation)
Cancellous chips are a common allograft material and for human use can
be procured readily from organizations such as the Musculoskeletal Transplant
Foundation. The process of production of this graft material, described earlier,
involves the use of freeze-dry cycles and irradiation to counteract the disease
transmission and immune reactivity risks associated with allografts. The
degradation of surface proteins and growth factors within the bone matrix during
this process results in the final porous scaffold product exhibiting severely reduced
or no osteo-inductive capabilities. Therefore, cancellous bone chips are primarily
utilized as osteoconductive filler matrices within non-weightbearing osseous
defects. A study conducted by Hall et al. (2018), assessed cancellous chips
derived from canine bone as a predicate material against a synthetic graft material
in a critically-sized axial defect in the proximal humorous of 13 hound-type dogs.
The administered cancellous chips ranged from 1-4mm and were acquired from
Veterinary Transplant Services, Inc. The humeri harvested at sacrifice (3 samples
at 6 weeks, 5 samples at 13 weeks, and 5 samples at 26 weeks) were examined
histologically to evaluate new mineralized bone and fibrous tissue formation.
Analysis of 13-week and 26-week samples revealed that cancellous chip treated
defects did exhibit enhanced healing and integration with native tissue at the
periphery of the implanted material, yet fibrous tissue formations were observed at
the center region of these defects. These formations were attributed to the poor
inductive ability of the allograft material resulting reduced capacity to facilitate
repair of critically-sized defects (Hall et al., 2018). Additional analysis of
compressive mechanical strengths of samples and percentage of residual material
compliment this finding with cancellous chip treated samples showing lower
mechanical strength and greater volumes of remaining material as compared to
the synthetic graft. As allograft products such as cancellous chips have been
observed to require as much as 1 to 3 years for complete healing of the treated
injury, it possible that the 26-week time point utilized in this study may account for
the low level of repair observed in this study (Hall et al., 2018).
Puros® (Zimmer Biomet)
Puros® is a mineralized cancellous bone allograft produced and distributed
by Zimmer Biomet and utilizes a Tutoplast® processing method. This process
provides a scaffold structure with preserved internal porous structure, surface
proteins, and matrix growth factors of the natural bone. The preservation of matrix
proteins and growth factors enable the grafting material to have osteo-inductive
capabilities in addition to the osteoconductive properties of the basal structure,
making such a material an attractive alternative to autologous grafts. A study
conducted by Reddy et al. (2016) assessed Puros® with relation to the
effectiveness of autologous bone grafts for treating periodontal intra osseous
defects over 6 months. Patients included in the study (n=10) were divided at
random into either Group A, receiving Puros® treatment (n=5), or Group B,
receiving autologous bone graft (n=5). The primary assessment was conducted
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through radiography of the defect region by evaluating changes in the defect depth
(DD) at 1, 3, and 6 months post-operative intervals. Each timepoint was compared
to baseline measurements. DD was determined based on parameters associated
with the cementoenamel junction (CEJ), the region of the interface between
enamel and cementum, including the relation to the most apical point of the defect
and to the most coronal point of the alveolar crest. Defects treated with Puros®
demonstrated significant decreases in depth size over each analyzed time point
and was found to be comparable to autologous bone in the percentage of defect
filled at the 6-month interval. It was concluded that both the Puros® and
autologous bone promote predictable periodontal regeneration (Reddy et al.,
2016).
RegenerOss® (Zimmer Biomet)
RegenerOss® is a partially demineralized, freeze-dried allogeneic product
produced and distributed by Zimmer Biomet that undergoes processing methods
designed to remove unwanted cellular elements while preserving lipids in the
tissue. The resulting product is recommended for primarily oral and maxillofacial
surgical procedures such as alveolar ridge augmentation, sinus floor elevation, and
tooth socket preservation, as per product page. As with previously discussed
allograft materials, RegenerOss® is not capable to provide sufficient mechanical
stability alone for use in weightbearing bony defects. Available product particle
sizes can range from 200-800μm and therefore offer variation in both surface area
and topographical elements that may aid in promoting osteoconductive
capabilities. In a case-controlled study by Eskan et al. (2017), 14 patients were
treated with the allogeneic bone graft in conjunction with a bioresorbable matrix
membrane for covering the defect region, and then placed into one of two groups,
those receiving primary wound flap closure and those with the primary wound left
exposed. The primary objective of the study was to assess the impact of initial
wound exposure with relation to regenerative and reparative capacities, as well as
to evaluate the effectiveness of the allograft material with membrane cover.
Treatments were analyzed based on alveolar ridge widths, with baseline
measurements conducted at initial surgical entry and final values taken after 4
months healing time during dental implant placement. Despite a lack of
significance between study groups in alveolar ridge width increase over the 4month period, all defects treated with the RegenerOss® product in conjunction with
the bioresorbable matrix membrane demonstrated a significant increase in mean
alveolar ridge width, indicating effective application of the allograft for osteoreparative functions in this model (Eskan et al., 2017).
Xenograft Products
Xenografts comprise of scaffolds and particles derived from non-human
species and therefore encompass a wide array of structural and protein
compositional characteristics. Xenografts have been an attractive alternative to
human-derived graft materials primarily due to manufacturing costs and enhanced
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availability of source material (Qiao et al., 2018). Additionally, the risk of disease
transmission is greatly reduced since the transplant material is no longer human
in origin, yet this also results in the material having a greater risk of evoking an
immune response due to foreign proteins and elements. To address this risk, raw
xenogeneic materials are subjected to the processes discussed earlier with
allogenic grafts, namely freeze-drying and demineralization procedures. Materials
that have undergone extensive freezing and lyophilization cycles to remove the
organic components of the tissue matrix are considered “anorganic” and offer an
inexpensive substitute for apatite structures that possess strong osteoconductive
characteristics (Lee et al., 2014). The general process utilized for this
decellularization of tissue can be observed in Figure 1.2. As these constructs do
not maintain effective/intact proteins within the matrix, products prepared through
this method do not generally demonstrate osteo-inductive capabilities. Currently,
the most prolifically utilized xenograft materials are of bovine origin; however,
grafts derived from porcine tissue have shown promise, due to architectural and
compositional similarities to human bone (Qiao et al., 2018).
The explored commercially available xenogeneic grafts consist of products
from both bovine and porcine origins, with varying processing methods. The
products: MinerOss XP®, BioOss®, InterOss®, and Gen-Os®, were selected
through a basic web-based search for commonly employed xenograft materials.
MinerOss XP® (BioHorizons)
MinerOss XP® is a porcine-derived bone particulate graft material produced
and distributed by BioHorizons. Similar to the previously discussed MinerOss®
allogenic chips, MinerOss XP® is designed to act as a filler agent for bony defects
that are non-weightbearing, as in cases as ridge and sinus augmentation. Source
tissue undergoes extensive washing and fat stripping processes to remove the
organic elements, including surface and matrix proteins, to eliminate factors that
may elicit a reaction in native tissue surrounding the implant site. The resulting
anorganic matrix is highly porous and maintains strong osteoconductive functions,
providing an environment favorable for new bone formation. The efficiency of
MinerOss XP® to form new bone (osteoid) was examined against a bone grafting
material of bovine origin, which is currently more commonly utilized for xenograft
applications, in a case study conducted by Guarnieri et al. (2017). The study
consisted of a comparative histological assessment of new bone formation in two
sockets that had received either the bovine or porcine-derived graft material. Core
samples from the sockets were taken 6 months initial extraction and material
application, during implant placement. Histological evaluation of the samples
indicated that the porcine-derived product resulted in an increased formation of
new bone as compared to the bovine-derived material, with percentage osteoid
being 32.19% and 26.85% respectively. Additionally, the porcine-derived material
demonstrated a reduced level of residual grafting material, an important
consideration for xenogeneic graft materials as it is indicative of ability of the host
to breakdown and resorb the graft (Guarnieri et al., 2017). Both materials utilized
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in the study demonstrated osteoconductive attributes and did not impede bone
formation at the defect site.
BioOss® (Geistlich)
Produced and distributed by Geistlich, BioOss® is a deproteinized bone
mineral particulate product of bovine origin. Deproteinization through common
processes such as calcination, the removal of non-mineral elements by thermal
degradation, or chemical treatments offer resulting graft products that consist
primarily of the mineral phase structures (Su et al., 2018). These structures have
inherently high porosities with varying pore sizes and intricate connecting
channels, which are essential attributes for material intended to provide osteoconductive effects. BioOss® has demonstrated significant enhancement of new
bone development when implemented in non-weightbearing bony defects,
particularly when incorporated as a supportive element to autologous bone
particulate. In a systematic review by Aludden et al. (2017) the comparative impact
of BioOss® as a standalone grafting material was assessed in relation to the
bovine-derived products’ coupling with autologous bone particulate in a selection
of human lateral ridge augmentation procedures conducted between January 1990
and May 2016. The study evaluated effectiveness of treatment options based on
two primary outcome criteria, the “survival of the suprastructure” and the “survival
of the implant” (Aludden et al., 2017). If the suprastructure integrity, the newly
formed bone matrix within the defect site, was determined to be compromised, this
was defined as a “total loss” as the implant site could not then be assessed.
Permitting that suprastructure was intact, the implant site was evaluated based on
integration with native tissue and impact on surrounding tissue. To further support
primary outcome classifications, measurements of histologically assessed new
bone formation, ridge dimensional elements, and patient-reported outcomes were
also incorporated into the study. It was determined that the variation in study
design of the non-comparative evaluations of BioOss® treatments that were
evaluated by Aludden et al. (2017) complicated the ability to accurately compare
the individual study results in a systematic review. Therefore, the review heavily
relied on secondary assessment characteristics to compare the two treatment
modalities. Histological results and ridge dimensional assessments, both two
dimensional and volumetric, indicated that there was not a significant difference
between the treatments. Furthermore, comparison of characteristics of BioOss®
mixed with autologous bone particulate against the application of purely autograft
material did not yield a significant variation in implant survivability, thereby
indicating the potential of BioOss® and similar xenogeneic-based graft materials
as effective alternatives.
InterOss® (Sigma Graft)
InterOss®, similar to BioOss®, is an anorganic bovine-derived bone
particulate graft material developed and distributed through SigmaGraft. The
process utilized for deproteinization consists of initial chemical treatment of the
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origin tissue with NaOH and H2 O2 solutions, followed by calcination at 350℃. The
resulting highly porous mineral structure is then capable of providing an
osteoconductive substrate for application in non-weightbearing bony defects. The
design and function of this material closely mimics the previously described
BioOss® graft material, which is the basis for a comparative study conducted by
Lee et al. (2014) of the SigmaGraft research and development department. The
study primarily focused on comparing the physical and chemical characteristics of
both materials including the surface area, porosity, and protein residue
measurements. Results of the evaluation of the products indicated that the mineral
composition and surface area of structures were not significantly different.
Likewise, the crude protein residue content was not significantly different between
the two materials, though it was speculated that the relatively lower content
observed in InterOss® may have been a result of the extended annealing process
(Lee et al., 2014). Another comparative study of these two graft materials was
conducted by Kim et al. (2017) to evaluate the impact of these materials when
applied to a complex in vivo system. The preclinical study utilized a critically-sized
mandibular alveolar ridge defect in canines and was assessed at 4, 8, and 12
weeks post treatment. 54 defects in 27 animals received either treatment with
InterOss®, BioOss®, or left empty. Histological and microcomputed tomography
were used to evaluate the new bone development at defect sites and indicated
that both materials were effective at facilitating new bone growth in relation to the
negative control group, though there was no significant difference between
products (Kim et al., 2017).
Gen-Os® (Tecnoss Dental)
Gen-Os® is a porcine-derived cortico-cancellous xenogeneic graft product
developed and distributed by Tecnoss Dental primarily for oromaxillofacial
applications. Conservation of origin tissue matrix structure enables graft particles
to serve as highly porous substrate material for facilitating osteoconductive
functions, much like previously described xenogeneic grafts. Additionally, GenOs® processing preserves the collagen content of the origin tissue, which
promotes osseo-integrative and osteo-inductive capacities.
The inherent
hydrophilic nature of the product due to the collagen content is also emphasized
as a potential carrier mechanism for select drugs (Figueiredo et al., 2013; Fischer
et al., 2015). A study evaluating the effectiveness of Gen-Os® as treatment in a
select population of healthy chronic periodontitis patients, with individuals
receiving graft product after debridement or only receiving open flap debridement.
Treatments were assessed through clinical rankings, including plague index,
gingival index, and pocket depth, and radiographical measurements of bone
density. Comparison of baseline values with results at 6 and then 12 months post
operation demonstrated that Gen-Os® significantly enhanced both clinical and
radiological outcomes (Attia, 2017).
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Synthetic Graft Products
Synthetic bone graft substitutes are those that are derived from non-organic
sources and consist of a broad spectrum of materials with varying characteristics.
Though many of these materials are polymeric-based, these constructs are
susceptible to high variability during synthesis and will not be further discussed in
this article. Focusing primarily on commonly employed ceramic-based grafting
materials, these materials consist of dense mineral structures that can be modified
to adjust porosity and surface topography. Such materials have demonstrated
promise in bone tissue regenerative application due to their ability to mimic the
structure of native bone and provide an osteoconductive substrate for tissue ingrowth. However, these materials do not inherently contain proteins or growth
factors that would allow for osteo-inductive functions and therefore must be
coupled with other materials or biological agents to elicit such activity.
The selected synthetic graft materials consist of ceramic-based mineral
products intended to act as osteoconductive constructs. The explored products
include hydroxyapatite nanocrystals, Chronos®, Syntoss®, and Vitoss® Synthetic,
and were produced via a rudimentary web-based search for commercially
available synthetic bone grafts.
Hydroxyapatite Nanocrystals (Berkley Advanced Biomaterials)
Synthetic hydroxyapatite nanocrystals (nHA) are a commonly employed
calcium-phosphate (CaP) salt that is identical in composition to naturally forming
hydroxyapatite (HA), which is a primary mineral element in bone (Sadat-Shojai et
al., 2013). nHA can be readily synthesized through simple chemical processing to
generate bulk quantities for a variety of applications. Additionally, pre-synthesized
nHA products are commercially available, such as products generated and
distributed by Berkley Advanced Biomaterials, for application as a standalone
material or in conjunction with other materials for enhancement of properties. The
nano-scale of this CaP significantly increases the surface area as compared to
micro-scale HA, thereby heavily impacting the osteo-conductivity of the material.
However, the high surface energy associated with the nanoparticles results in a
propensity for particles to agglomerate and form macrostructures with significantly
different characteristics (Fu et al., 2017). These varying microscale topographical
landscapes can result in substantially different cell-material interactions and
influence both cytocompatibility and cell differentiation characteristics (Jackson et
al., 2018). nHA has demonstrated strong biocompatibility and is readily
internalized by native cells, resulting in modulative effects on gene expression (Ha
et al., 2015; Santos et al., 2017). These particles can also be readily incorporated
with various material structures as a surface coating or integrative component,
permitting design of composite graft materials that facilitate new bone formation
(Bow et al., 2019).
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ChronOs® (DePuy Synthes)
ChronOs® is a synthetic β-tricalcium phosphate (β-TCP) bone grafting
material produced and distributed by DePuy Synthes. β-TCPs are a commonly
implemented material for bone grafting applications due to inherent
biocompatibility, as well as resorbable and osteo-conductive functions (Arbez and
Libouban, 2017). As with the previously described synthetic nHA material, β-TCPs
like ChronOs® are often used in conjunction with other mineral or bioactive
components. In materials such as Syntoss®, a bone graft substitute produced by
Dental Solutions Israel, β-TCP is combined with HA for an osteo-conductive
porous structure (no available peer reviewed publications for Syntoss®).
However, as a standalone grafting material ChronOs® has demonstrated
effectiveness as a readily available bone void filling agent in non-weightbearing
structures. In a study conducted by Bonardi et al. (2018), ChronOs® was
examined alongside autogenous bone grafts and BioOss® in a human maxillary
sinus bone augmentation procedure. The results indicated that ChronOs® was
not significantly different from autogenous bone grafts in new bone formation,
residual material, or area of connective tissue; however, ChronOs® did display
significantly less residual material than those treated with BioOss®. ChronOs®
therefore offers an attractive alternative bone grafting material, particularly when
coupled with autogenous bone particulate which can provide an osteo-inductive
characteristic (Bonardi et al., 2018).
Vitoss® Synthetic (Stryker)
Vitoss® is a synthetic cancellous bone developed and distributed by Stryker
as a bone graft substitute for bony voids in intrinsically non-weightbearing
structures. This CaP grafting material is designed to be highly porous with
complex inter-pore channels to mimic the structure of natural bone. The matrix
composition and structure enable Vitoss® to exhibit both biocompatible and osteoconductive characteristics, and when coupled with bioactive agents can serve as
an osteogenic substrate. In a prospective multi-cohort study conducted by Epstein
et al. (2015), Vitoss® is compared to NanOss, a bioactive material composed of
nano-scale CaP and porcine-derived collagen matrix, to assess the effectiveness
of the materials in patients receiving laminectomies followed by posterior cervical
fusions. The first cohort (n=72), were treated with a combination of autografts,
bone marrow aspirate, and Vitoss®, while the second cohort (n=20) received the
NanOss® in place of Vitoss®. Findings indicated that both examined material
treatments yielded comparable fusion times and did not demonstrate significantly
different fusion characteristics (Epstein, 2015).
Bioactive Graft Products
Bioactive materials comprise of a wide array of compounds ranging from
osteogenic-related proteins, such as bone morphogenic protein-2 (BMP-2), to
genetic manipulation of native cells using nucleic acid, i.e. plasmid DNA (pDNA)
and chemically-modified RNA (cmRNA), or viral-based approaches. For this
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reason, the application of bioactive materials varies dramatically based on the type
of compound with many requiring a delivery mechanism to enhance effectiveness
or duration of effect. This coupling with existing technologies permits development
of finely-tuned grafts capable of facilitating bone repair via a tailored set of
mechanisms, and therefore offers a highly attractive alternative to traditional bone
graft substitutes. For this reason, the application of bioactive molecules in
combination with traditional osteobiologic substrates has garnered the focus of
many researchers in the field of bone tissue engineering. However, many of these
agents are restricted in commercialization potential due to inherent costs and time
associated with developing materials classified as drugs by the U.S. Food and
Drug Administration (FDA) (Hasan et al., 2018). Furthermore, treatments utilizing
bioactive materials may in some cases increase the risk of side effects in the local
tissues or lead to tumorigenic growth. Therefore, limited products in this category
are readily available commercially, which consequently results in products
themselves being expensive, and are restricted to specific applications.
The bioactive graft materials selected for this review consist of growth
factor-based molecules added to traditional osteobiologic grafts, such as those
discussed above, in order to enhance or better regulate osteogenic activity. The
products described here include InfuseTM and GEM 21S®, which were produced
via a rudimentary web-based search for commercially available FDA-approved
bioactive materials.
InfuseTM (Medtronic)
BMP-2 has been demonstrated to be closely associated with osteogenesis
(Schuberth et al., 2009), particularly with relation to mineralization, and is the only
FDA-approved osteo-inductive growth factor currently available for bone grafts
(James et al., 2016). The InfuseTM product produced and distributed by Medtronic,
consists of an absorbable collagen sponge scaffold seeded with recombinant
human BMP-2 generated using a hamster oocyte production cell line for protein
recombination. Chinese hamster ovary (CHO) cell-derived rhBMP-2 maintains
potent osteo-inductive potential, but, as a consequence of production costs,
remains an expensive product. Comparative studies examining the osteoinductive potential of CHO cell-derived rhBMP-2 with a relatively cheaper
manufacture process utilizing Escherichia Coli (E. Coli)-derived rhBMP-2, which
permits increased protein yield, have thus far indicated that the CHO cell-derived
protein boast superior osteo-inductive potential (Jin et al., 2019). As per the
InfuseTM product page, the bioactive product is indicated for only specific
applications in spinal fusion procedures and acute tibial shaft fractures. The
primary reason for the observed limited application of the product are likely related
to the potential side-effects associated with administering growth factor doses in
vivo. As discussed in James et al. (2016), adverse effects of BMP-2 can range
from surgical site inflammation to ectopic bone formation. This is particularly
concerning when considering applications related to spinal fusion and further
stresses the importance of adherence to product guidelines.
13

GEM 21S® (Lynch Biologics)
GEM 21S® is a growth-factor-enhanced matrix (GEM) material produced
and distributed by Lynch Biologics for use in dental therapy applications. The
bioactive product is comprised of purified recombinant human platelet-derived
growth factor-BB (rhPDGF-BB), derived from yeast cultures, seeded to a βtricalcium phosphate (β-TCP) (Singh and Suresh, 2012), similar in design to the
previously discussed ChronOs®.
PDGF-BB is strongly associated with
angiogenesis and has been demonstrated to be produced by osteoclasts during
osteogenesis for recruitment of precursor cells (Xie et al., 2014). The combination
of the growth factor with an osteoconductive matrix, β-TCP, is intended to promote
healthy bone repair by recruitment of progenitor cells and formation of vasculature
within the scaffold. In a study conducted by Young et al. (2009), the GEM 21S®
product was examined for protein release dynamics in vivo using a calvarial defect
in rats. It was observed that the protein underwent a rapid burst release, with
complete depletion of the protein by 72 hours post-implantation (Young et al.,
2009). Despite the release rate of the protein it was observed that the rhPDGFBB was still bioactive in the surrounding tissue. A separate comparative study
examined the use of GEM 21S® with a collagen membrane for dental recession
defects to determine if the product was capable of enhancing root coverage as
compared with a collagen membrane alone (Singh and Suresh, 2012). Though
root coverage in the GEM 21S® treated samples appeared improved, the
researchers noted that no significant difference was observed between the study
test groups.

Conclusion
The bone graft materials discussed in this section (Table 1.1), represent a
small portion of currently available biomaterials for bone tissue engineering
applications; however, these products demonstrate the fundamental osteobiologic
characteristics for materials designed to act as effective bone tissue engineering
grafts. Though, as the different processing methods used to generate these
products result in an array of grafts that display highly variable reparative functions,
an ideal bone substitute graft is still yet to be developed. This is further echoed in
the low mechanical structural integrity of these materials restricting application
primarily to non-weightbearing injury sites. For these reasons, the previously
described materials serve as the more commonly applied bone grafts substitutes
and are utilized as basal elements of more complex scaffold composite designs.
As the majority of these products exhibited osteo-conductive and biocompatibility
qualities, coupling bioactive components, such as growth factors, with the
materials can offer enhanced functions including osteo-inductive and osseointegrative characteristics (Zhao et al., 2017). Furthermore the implementation of
cell-based or gene therapy-based approaches can serve to generate osteogenic
environments capable of facilitating finely-tuned bone repair (Hasan et al., 2018).
Utilizing polymer-based additives to matrix compositions can result in grafts with
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both hard mineral and pliable elastic regions, thereby mimicking mechanical
diversity in natural bone. Additionally, hydratable polymers may provide optimal
means for carrying and eluting drugs at the site of interest. Drugs capable of
preventing infection of the treated site or stimulating the native tissue to facilitate
enhanced reparative characteristics, can be readily incorporated into multicomposite structures comprised of any number of the discussed materials and a
polymeric binding agent to develop a scaffold material that could far exceed the
capabilities of even autologous grafts. Such novel combinations of available
technologies provide an ever-expanding arsenal of graft options for treating bone
injuries and represent the impressive potential of bone tissue engineering.
However, determining the optimal graft technology for replacement of autografts
will require continued concentrated research efforts in both benchtop and clinical
trial settings to ensure an effective and superior osteobiologic product.
The experimental osteobiologic materials discussed in this work were
designed for enhancing the repair and restoration time frame of bone injuries, in
both endochondral and intramembranous sites, as compared with currently
available graft technologies. Furthermore, the various composites offer a relatively
inexpensive and readily synthesizable alternative. The majority of the composite
materials discussed will be comprised of polyurethane (PU), nano-hydroxyapatite
(nHA), and decellularized bone particles (DBPs) in varying ratios and with multiple
fabrications techniques. Of these materials, most iterations employ a degradable
PU known as D3 (https://plastics.ulprospector.com/datasheet/e155789/hydromedd3), while the variant utilizes a PU with enhanced hydrophilicity to provide for
increased material swelling. Additionally, two materials were examined that
implement a combinatorial design of nHA and Pluronic f-127 (PF127)
(http://phm.utoronto.ca/~ddubins/MSDS/Poloxamer_407_MSDS.pdf) also known
as Poloxamer 407, with one iteration also including quaternized chitosan (Luan et
al. 2018). These alternative designs were intended to provide an osteobiologic
matrix that was injectable, as the PF127 is a thermosensitive block polymer
capable of reversible gelling.
To accurately and completely assess these graft materials for
biocompatibility, osteogenic potential, and general effectiveness, a wide array of
experimental techniques was utilized, each with appropriate controls and study
design. These processes will be discussed in-depth within respective chapters but
range from in vitro characterization techniques, such as cellular viability stains and
polymerase chain reaction (PCR), to tissue assessment through
immunohistochemistry (IHC). Controls for these experiments were tailored to
elucidate material action on a particular system, either in vitro or in vivo, or to draw
comparisons with commercially available grafts. For comparative studies,
predicate devices were selected that best resembled the structure and application
method of the examined test article.
The application and assessment of a wide array of materials including
experimental iterations, predicate devices, the basal construct components of
these (both mineral and organic), and the potential of incorporating various biologic
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additives has demonstrated the expansiveness of the bone tissue engineering
field. The improvement of existing technologies in this field, either through
combination of currently available components or the synthesis of new additives
and fabrication methods, offers an ever-advancing arsenal of biomedical tools for
treating and restoring function of complex bone injuries and diseases. This work
represents a minute fraction of this advancement yet serves as an example of the
investigative effort required to effectively assess a previously unexamined bone
graft design.
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Appendix

Figure 1.1. Generalized flow chart diagram for demineralization of bone tissue. Process moves
from origin bone tissue to low mineral/high organic content product.
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Figure 1.2. Generalized flow chart diagram for decellularization of bone tissue. Process moves
from origin bone tissue to high mineral/low organic content product.
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Table 1.1. Overview of bone graft materials. List detailing general information and characteristics
of discussed bone graft technologies. In addition to graft type and source, material content and
application references are listed.
Graft Material

Company

Graft Type

Graft
Source

Inorganic
Content

Organic
Content

In Vitro
Application
Reference(s)

Grafton DBM

BioHorizons

Allogenic

Homo
Sapien

No

Yes

Kumaran et al.
2010

MinerOss

BioHorizons

Allogenic

Homo
Sapien

Yes

No

Greenspan 2012

RaptOs

Citragenix

Allogenic

Homo
Sapien

Yes

No

Kaya et al. 2015;
Kolerman et al.
2019

Cancellous
Chips

Musculoskeletal
Transplant
Foundation

Allogenic

Homo
Sapien

Yes

No

Hall et al. 2018

Puros

Zimmer Biomet

Allogenic

Homo
Sapien

Yes

Yes

RegenerOss

Zimmer Biomet

Allogenic

Homo
Sapien

Yes

Yes

Eskan et al. 2017

MinerOss XP

BioHorizons

Xenogeneic

Porcine

Yes

No

Guarnieri et al.
2017

Greenspan 2012

BioOss

Geistlich

Xenogeneic

Bovine

Yes

No

Jackson et al.
2018; Xu et al.
2019

InterOss

Sigma Graft

Xenogeneic

Bovine

Yes

No

Lee et al. 2014

Gen-Os

Tecnoss Dental

Xenogeneic

Porcine

Yes

Yes

NanoHydroxyapatite

Berkley Adv.
Biomaterials

Synthetic

N/A

Yes

ChronOs

Depuy Synthes

Synthetic

N/A

Vitoss

Stryker

Synthetic

nanOss

rti Surgical

Synthetic

In Vivo
Application
Reference(s)
Bomback et al.
2004; Brecevich et
al. 2017; Kadam et
al. 2016; Kang et
al. 2012
Avila et al. 2010;
Potres et al. 2016

Reddy et al. 2016

Aludden et al.
2017; Bow et al.
2019; Kumar et al.
2018; Sohn and
Moon 2018; Xu et
al. 2019
Kim et al. 2017
Attia 2017;
Figueiredo et al.
2013; Fischer et al.
2015

No

Fu et al. 2017; Ha
et al. 2015;
Jackson et al.
2018; Santos et al.
2017

Bow et al. 2019;
Pujari et al. 2016

Yes

No

Arbez and
Libouban 2017

Bonardi et al.
2018; Kanter et al.
2016

N/A

Yes

No

Epstein 2015;
Walsh et al. 2013

N/A

Yes

No

Epstein 2015;
Walsh et al. 2013
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CHAPTER II:
IN VITRO ASSESSMENT OF IMMORTALIZED PRE-OSTEOBLAST
CELLS ON POLYURETHANE MATRICES IMPREGNATED WITH
NANO-HYDROXYAPATITE
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Abstract
A wide variety of biomaterials are utilized in tissue engineering to promote
cell proliferation in vitro or tissue growth in vivo. The combination of cells,
extracellular matrices, and biocompatible materials may make it possible to grow
functional living tissues ranging from bone to nerve cells. In bone regeneration,
polymeric scaffolds can be enhanced by the addition of bioactive materials. To this
end, this study designed several ratios of polyurethane (PU) and nanohydroxyapatite (nHA) composites (PU-nHA ratios: 100/0, 90/10, 80/20, 70/30,
60/40 w/w). The physical and mechanical properties of these composites and their
relative cellular compatibility in vitro were determined by the research team at
UALR. The results showed a significant increase in surface roughness and a
decrease in contact angle when the nHA concentration increased above 20%,
resulting in a significant increase in hydrophilicity. These surface property changes
influenced cellular behavior when MC 3T3-E1 cells were seeded on the
composites. All composites were cytocompatible. There was a linear increase in
cell proliferation on the 80/20 and 70/30 composites only, whereas subjective
evaluation demonstrated noticeable clusters or nodules of cells (considered
hallmarks of osteogenic differentiation) in the absence of any osteogenic inducers
only on the 90/10 and 80/20 composites. Cellular data suggests that the 80/20
composite was an optimal environment for cell adhesion, proliferation, and,
potentially, osteogenic differentiation in vitro.
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Introduction
Tissue engineering, a field that merges engineering with medical research,
utilizes materials with complex bio-physico-chemical properties and living cells to
either generate tissue in vitro or promote rapid tissue growth in vivo. With the
development of materials that have tunable characteristics, new areas of research
have emerged related to the regeneration of missing tissues due to trauma,
disease, or military exercises. Within this field, bone tissue engineering focuses
on assisting bone growth, healing, or regeneration. Bone injuries often require
prolonged periods of time to heal and can cause long-term problems if they do not
heal properly. Simple fractures usually heal without complicated therapies, but
complex fractures involving shattered or missing bone often require void filling, a
scaffold to guide healing, or a construct to support the area and/or assist in healing.
Several types of scaffolds are used in bone tissue engineering, from collagenbased materials (Ferreira, Gentile, Chiono, & Ciardelli, 2012; Sun, Zhu, Hu, &
Krebsbach, 2014; Bayer et al., 2013) and polymer composites (Lou et al., 2015;
Goncalves et al., 2015; Liao, Cui, Zhang, & Feng, 2004; Hutmacher, 2000) to
particle-based pastes and cements (Kobayashi et al., 1998; Harper & Bonfield,
2000). Porosity and mechanical integrity are important properties of a successful
scaffold (Liu, Hunziker, Randall, de Groot, & Layrolle, 2003; Biswas et al., 2010;
O'Brien, 2011). Bone tissues have inherent properties that create a porous
environment while still providing strength and rigidity. However, these properties
vary significantly based on the location of the osseous tissue in the body.
Therefore, increased research attention has been given to matching the properties
of the scaffold used in regenerative applications with the characteristics of the
tissues to be regrown. Bone scaffolds can be improved through biomimetics (Su
et al., 2016), the study and imitation of naturally occurring properties. In the past,
biomimicry has not been a significant factor in bone tissue engineering, but
recently, it has led to the creation of successful bone scaffolds. Bones are
hierarchical materials, meaning that they are composed of layers containing large
components, which are made up of smaller components. Specifically, bone is
comprised of “brick and mortar” structures, with a hard, plate-like inorganic
substance supported by a softer organic component (Gao, 2006; Egan, Sinko,
LeDuc, & Keten, 2015; Meyers, McKittrick, & Chen, 2013). These brick and mortar
structures add mechanical stability to bone by dispersing forces through the matrix,
especially when a plate-like material is arranged preferentially in load-bearing
directions (Egan, Sinko, LeDuc, & Keten, 2015). To mimic these components of
natural bone, scaffolds can be constructed using polymers with various sizes of
particles loaded into them, thereby creating a composite matrix. The advantages
of such materials are significant—they can be formed in different shapes, have
tunable mechanical properties, can support cellular proliferation, and may be
biodegradable.
Many current composite bone scaffolds must be removed after the bone is
healed or to allow the bone to complete the healing process, in order to prevent
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residual materials from damaging the body. The scaffolds used in this study were
designed with biocompatible polyurethane (PU) and nano-hydroxyapatite (nHA) as
the soft and hard components, respectively. Generally, PU degrades via
hydrolysis, but the overall process is complex and highly dependent on its structure
and chemical composition (Adhikari et al., 2008; Zhang et al., 2016). The PU used
in this study was desirable because it is biologically stable for up to 30 days after
implantation. This limited durability will give the scaffold structural stability during
the initial stage of natural bone growth, after which it slowly, safely degrades. HA
is a crystalline structure that is naturally occurring in bone but can also be
generated synthetically. As such, HA does not generally cause any adverse
effects on the body and should assist in bone cell viability with the potential to be
integrated into the natural bone. It has been reported that nano-hydroxyapatite
exhibits better cellular response for bone regeneration compared to microHA
(Christenson et al., 2007). Therefore, our intent is to evaluate several composites
with varied ratios of nHA that are incorporated into a polyurethane that serves as
a binding agent to hold the nHA particles together. To this aim, we can determine
an optimal concentration from in vitro cellular proliferation studies which would then
assist in the design of 3-dimensional scaffolds for in vivo studies.
Vital to the development of biomaterials is the assessment of the
cytocompatibility and effect on cell activity of the material (Salgado, Coutinho, &
Reis, 2004). This is accomplished through in vitro evaluation of cell response
utilizing commercially available cells, such as the MC 3T3-E1 cell line (ATCC). MC
3T3-E1 is a cell line of mouse (Mus musculus) calvaria preosteoblast cells
commonly used in studies related to bone differentiation and is one of the most
convenient and physiologically relevant systems for study of osteogenic control of
osteoblasts. A spontaneously immortalized cell line, MC 3T3-E1 behaves as
immature, committed osteoblast cells. The cell phenotype is very stable and
rigorously maintained (Towler & Arnaud, 2002).
In this study, we utilized a commercially available, biocompatible, and
solution processible ether based polyurethane and incorporated nanohydroxyapatite in a simple mixing process. We hypothesized that by varying the
concentrations of nHA, we will generate composites of similar mechanical stability
and mineral type, but varying in their surface properties, which will affect cellular
behavior. These evaluations will focus on generating platforms for bone tissue
engineering. To test our hypothesis, we generated four compositions of PU-nHA
composite films (in addition to a 100/0 PU-nHA that served as a control), which
were characterized by the material research team at UALR using mechanical and
physicochemical techniques. Characterization techniques provided information on
the consistency of the films’ chemical, physical, and mechanical properties.
Subsequently, mouse preosteoblast and immortalized MC 3T3-E1 cells were
seeded on these films to evaluate the films’ cytocompatibility and cell behavior.
These studies were performed to determine the best composite ratio that should
be used to generate a 3D bone scaffold.
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Material Film In Vitro Work
MC 3T3-E1 Cell Culture Parameters
Commercially obtained MC 3T3-E1 cells (ATCC) were seeded in tissue
culture polystyrene-treated flasks and cultured at 37°C and 5% CO2 in αMEM
media with 10% fetal bovine serum and 1% penicillin streptomycin. The αMEM
media along with the serum and the antibiotics constitute the growth medium.
Media was replaced every 2–3 days, and the cells were passaged when they were
approximately 90–95% confluent. Confluent cells were exposed to 0.25% Trypsinethylenediaminetetraacetic acid solution for 2 minutes at 37°C and collected. Cells
were counted using a hemocytometer with Trypan Blue staining. For osteogenic
differentiation, growth medium was supplemented with 50 µg/mL ascorbic acid, 10
mmol/L β-glycerophosphate, and 10 nmol/L dexamethasone.
For cell culture, the PU-nHA-layered coverslips were placed material-side
down into individual wells of a non-tissue culture-treated plate and exposed to
growth media for at least 1 hour to separate the material film from the coverslip, at
which point the glass coverslip was removed from the well. This was done to
ensure that the cells adhered to the material films only. Finally, the cells were
seeded on the films. Seeding density and culturing parameters were dependent
on the type of experiment.
Each in vitro assay was carried out simultaneously, using an equal number
of cells seeded on the films and the polystyrene tissue culture surfaces. Cells
seeded on the polystyrene surfaces served as positive controls, and negative
controls were materials and polystyrene surfaces without any cells. Each assay
was performed at least twice with each sample in triplicate.
Commercially available MC 3T3-E1 cells adhered to all the iterations tested,
and initial evaluations showed that the cells proliferated on all films except the
60/40 iteration. Visual inspection indicated that cells were not healthy and nonproliferative, and hence, the 60/40 iteration was not used in subsequent in vitro
assays. Furthermore, 60/40 was not used to quantitate cell proliferation using the
calcein-am assay.
Viability and Proliferation
Calcein-AM staining, coupled with the quantitation of fluorescent intensity,
was used to assess cell proliferation and viability on the PU-nHA films. A
fluorescence assay was carried out in black-walled 24-well plates to eliminate
potential auto-fluorescence. 40,000 cells were seeded per film (1 film per well),
and the cells were incubated in growth media for 3, 5, and 7 days. For evaluation,
samples were incubated with 0.5 mL of staining solution, containing 10 μg/ml
calcein-AM reconstituted with dimethyl sulfoxide, at 37°C for 5 minutes, and the
fluorescence intensity was measured using a microplate reader set at an excitation
wavelength of 485 nm and an emission wavelength of 528 nm. Sample readings
were adjusted using the negative control readings. Replicates of materials were
averaged, and a graph of fluorescence intensity over the experimental timeframe
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was generated. Simultaneously, fluorescent images of all samples at each time
point were taken to verify the presence of cells and their viability.
Cell proliferation and viability was confirmed on the 100/0, 90/10, 80/20 and
70/30 composites using Calcein-AM staining over a period of 7 days (Figure 2.1).
Calcein-AM is a hydrophobic, non-fluorescent dye that infiltrates live, intact cells,
and is hydrolyzed by intracellular esterases, a process that converts the CalceinAM to calcein. Calcein-AM is hydrophilic, has strong green fluorescence, and is
retained by the cytoplasm of the cell, making it an indicator of cell health.
Fluorescence intensity is proportional to the quantity of viable cells, and therefore,
quantitative measurements of change in total fluorescence intensities over a given
period are indicative of cell proliferation (Crisan et al., 2015). As a result, CalceinAM staining serves a dual purpose of imaging viable cells and measuring their
proliferation. This strategy becomes particularly valuable when cells are seeded
on composite films, which cannot be imaged using standard microscopic methods.
Green fluorescent imaging (Figure 2.1) and quantification confirmed that all four
iterations of the films were biocompatible with the MC 3T3-E1 cells. As judged by
the fluorescence intensities of cells, there was a linear increase in cell proliferation
(R2 > 0.9) on the 80/20 and 70/30 films only (Figure 2.1). Though there was an
increase in cell fluorescence on the 90/10 film on day 3, the intensity changes were
not linear over days 5 and 7. 100/0 films demonstrated no linearity among time
points, with values initially increasing before a slight reduction.
Morphological Assessment
Direct labeling of MC3T3-E1 cells with DiI (1,1'-dioctadecyl-3,3,3',3'tetramethylindocarbocyanine perchlorate) was used to assess cell morphology on
the films. In a typical labeling reaction, 50 μg/ml DiI was used to label 1 million
cells. Cells were incubated at 37°C for 15 minutes and excess DiI was removed
by washing with HBSS (Hank's balanced salt solution). Cells were then resuspended in complete growth media. As described above, 40,000 cells were
seeded per film (per well) in a 24-well plate then incubated in growth media for 7
days. Images of five random areas on each sample and the corresponding
controls were taken once a day for seven days to visualize and track the growth
patterns and morphology of cells. The exposure time and magnification were kept
constant during imaging.
Cell morphology and viability over time were confirmed using the redfluorescent cytoplasmic DiI stain (Figure 2.2). DiI staining does not compromise
the integrity of the cellular membrane and allows us to image the same cells in real
time. This eliminates the need to harvest or fix cells to visualize changes in
morphology using microscopy. The formation of clusters of cells or “nodules” is
considered the hallmark of osteogenic differentiation and demonstrates bone
metabolic activity (Declercq, Verbeeck, De Ridder, Schacht, & Cornelissen, 2005).
Therefore, changes in cell morphology, indicative of osteogenic differentiation
profiles, were evaluated subjectively and quantitatively by imaging the nodules
formed when the MC 3T3-E1 cells adhered and proliferated on the films.
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Quantitative measurements were conducted using ImageJ software to categorize
nodules by size based on reference nodules in cultures on 100% PU films stained
with alizarin red for calcium content (Figure 2.3). Particular attention was given to
nodules in the Rank 4 category, designated as large nodules, and the average
area of these nodules was examined in cell-seeded material across time points
(Figure 2.4). Over time, cells on 90/10 and 80/20, PU-nHA films presented signs
of cell-cell communication and formation of dense nodular structures. Cells
seeded on the 70/30 composite films did show some signs of cell-cell
communication, but the pattern was not as striking as observed on the 90/10 and
80/20 films. All three film iterations demonstrated an increase in large nodule area
coverage between day 3 and day 7 time points (Figure 2.4). Cells exposed to
60/40 and 100/0 films did not display similar interactions, appearing as static,
spherical elements suspended in the films.
Since, the MC3T3 E1 cells showed evidence of cell clusters and
communication, we next investigated the cell morphology changes on 90/10 and
80/20 films in presence of the osteogenic differentiation medium (Figure 2.2).
Nodular structures observed in growth media supplemented with osteogenic
inducers, dexamethasone, beta-glycerophosphate, and ascorbic acid differed in
appearance from structures observed in presence of growth medium alone. Cells
seeded on the films and osteogenic differentiation medium exhibited signs of
stress. Structures present on samples in presence of the osteogenic inducers
displayed a lack of cell-cell communication and were not as dense as clusters
present in samples exposed to the films in the absence of osteogenic inducers.
This indicates that the cells in samples supplemented with differentiation medium
may have been exposed to culture conditions leading to excessive stress and
sporadic differentiation. Taken together, all data suggest that the cells seeded on
90/10 and 80/20 PU-nHA films show signs of osteogenic differentiation in the
absence of any osteogenic inducers.

Conclusion
In conclusion, our results demonstrated that by varying the nHA content,
the cellular response is affected, and by evaluating this response, we were able to
identify a composite which could potentially be used to design a 3D scaffold for
future in vivo studies. The chemical, physical, and mechanical properties of all the
composite films showed consistency and reproducibility for each preparation.
While the mechanical properties did not exhibit any significant changes, there were
statistically significant differences in the surface roughness and the contact angle
of the composites. The cellular response to each iteration can thus, be attributed
to this composition change as well as surface topography.
In vitro assessment of MC 3T3-E1 cells on these films presented inherent
challenges resulting from the compositional make-up of the material. The inclusion
of PU and nHA within the nanocomposite prevented use of common assays for
proliferation (MTS assay) and differentiation (Alizarin Red staining). Formazan
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crystal products were unable to be readily released into the surrounding media
when subjecting solutions to MTS reagent, thereby resulting in unreliable readings
for proliferation of cells on the films. To circumvent this issue the earlier describe
Calcein-AM fluorescent analysis was conducted to determine cell viability and
proliferation. Similarly, the presence of nHA in the material demanded an
alternative method to traditional alizarin red staining for evaluating the osteogenic
differentiation potential of cells on films. As this reagent works by staining calcium
to identify mineralized regions, the presence of calcium-rich additive in the material
resulted in prolific background that heavily obscured signal (Figure 2.5). Initially,
an alkaline phosphatase kit was attempted to assess osteogenic differentiation
potential, yet this assay appeared to face similar issues as the previously
attempted MTS assay and results were determined to be unreliable. The use of
the earlier described DiI fluorescent stain was therefore implemented to track cell
morphology over the study time course and attempt to correlate nodule formation
observed on films with similar nodules in PU-only material iterations and cell
monolayers to examine the osteogenic potential of film iterations.
The proliferation on different film compositions (as described above)
showed that all of the composites are cytocompatible. This claim is supported by
observation of cells through two separate stains, Calcein AM and DiI (Figures 2.12.2). Proliferative ability of cells exposed to 70/30 and 80/20 compositions
appeared normal and unhindered, based on their linearity. The early spike and
sequential plateauing of readings for cells exposed to 90/10 may be due to the
relatively low surface roughness in the film (Figure 2.1) which may not be
conducive to cell proliferation, and hence, lack reactivity in the proliferation assay.
The exact reason for the initial increase is not known at this time and is beyond the
scope of this study. Clustering and cell-to-cell communication of MC 3T3-E1 cells
on 90/10 and 80/20 films suggest that the cells are probably undergoing
osteogenic differentiation in the absence of any inducers, which can be proved
using in vivo models. This is further supported by the fact that during proliferation,
cells exhibited healthy morphology and cell-cell communication, in contrast to the
effects observed in the presence of osteogenic differentiation medium.
Our data suggests that the material properties, and specifically the nHA
content do influence cell behavior, which we could subjectively evaluate using the
cellular assays described in this study. Even though the 90/10, 80/20, and 70/30
composites all supported cellular proliferation, only the 90/10 and 80/20 showed
clustering of cells. In contrast, cells did adhere to the 60/40 composite, but, did
not proliferate, and hence, did not demonstrate any clusters or cell-to-cell
communication. This was an unexpected finding because an increase in the
percentage of nHA should promote cell adherence and osteogenic differentiation.
There are many published reports where authors have demonstrated that
surface roughness can significantly affect cell attachment, proliferation, apoptosis
and osteogenic differentiation. Studies have demonstrated that surface roughness
is a very important aspect of a biomaterial which can significantly modulate cell
behavior and hence, an optimal surface roughness has to be identified (Deng et
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al., 2015). More specifically, osteogenesis, induced by osteoblastic cells, is
characterized by a sequence of events, involving cell attachment and cell
proliferation, followed by the expression of osteoblast phenotype, is highly
dependent on the surface topography of biomaterials. It has been suggested that
the surface composition and structure of biomaterials can influence the adsorption
of the extracellular matrix proteins including fibronectin and vitronectin, which play
a very significant biological role in cell adhesion. Modulation of the osteogenic
differentiation process by various surface textures has been demonstrated by
evaluating changes in the alkaline phosphatase activity or in the expression
profiles of osteogenic-specific genes using immortalized (MC3T3E1 or MG-63
cells) or primary (mesenchymal stem cells) cell lines.
In view of these reports, we believe that the high surface roughness in the
60/40 composites affect the cellular adherence and thus, proliferation which could
potentially affect osteogenic differentiation. Taken together, linearity in cell
proliferation coupled with changes in morphology and formation of cell clusters,
suggests that the composite containing 20% nHA and 80% PU presents an
environment conducive for cells to adhere, proliferate and form clusters suggesting
osteogenic differentiation. Future in vivo experiments using these 80/20 films
should be investigated in order to further assess the osteogenic potential of cells
on such composites in an in vivo bone defect model.
As the current thin film form of the material does not resemble or address
the complex architecture of bone, or lend to ease of application, a 3D construct
design was developed based on both the 80/20 and 90/10 films. The new scaffold
material comprised of layers of these films interspersed with decellularized bone
particles (DBPs) to fabricate two scaffolds with inherent porosity that contains
micro- and nano-architectural elements. Scaffolds based on the 80/20 material
were designated as S-1, while those based on 90/10 films were S-2. This design
was hypothesized to maintain the cytocompatibility and potential osteogenic
functions of the film material while providing a more clinically applicable material
for treating bone injuries. To test this hypothesis, both in vitro and in vivo
assessment of the 3D scaffold design was performed, first to verify
cytocompatibility on the layered structure, and then to determine biocompatibility
and osteogenic capacity in an animal model. Since rodent models are a wellestablished method for early-stage biocompatibility studies, due to availability,
cost, and low inter-animal variance, a unicortical tibial defect model in rats was
utilized. This work and resulting data are detailed in the following chapter.
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Figure 2.1. Cell viability/proliferation using Calcein-AM staining. (a.) Calcein-AM and (b.) Calcein
AM staining fluorescence intensities. Asterisks indicate significant linear increases in fluorescence
intensities over a period of 7 days. Note: All samples were subjected to an initial evaluation where
only days 3 and 7 were analyzed. As the 60/40 sample did not exhibit healthy proliferation and
therefore was not included in the more extensive follow-up study of 3,5, and 7 days nor was
statistical analysis performed. However, the preliminary images from the 60/40 film are presented
for reference.
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(a)

(b)

Figure 2.2. Cell morphology using DiI staining. DiI fluorescently labeled cells exposed to 100/0,
90/10, 80/20, 70/30, and 60/40 films in growth media (a). Note: All samples were subjected to an
initial evaluation where only days 3 and 7 were analyzed. As it was determined that the 60/40
sample did not exhibit healthy proliferation and therefore was not included in the more extensive
follow-up study of 3,5, and 7 days. However, the images from the 60/40 film are presented for
reference. DiI fluorescently labeled cells exposed to 90/10 and 80/20 films in osteogenic
differentiation media (b) (supplemented with osteogenic inducers, dexamethasone, betaglycerophosphate, and ascorbic acid) shown for reference at day 7 only.
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Figure 2.3. Cell nodule identification utilizing ImageJ processing of DiI stained samples. (a)
Reference nodule sizes from cell cultures on 100% PU films were used to assess fluorescently
labeled cells by assigning nodules in (b) original fluorescent image with (c) ranks. (d) Binary masks
for images were generated with ImageJ and (e-h) nodules were isolated based on size ranking.
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Figure 2.4. Nodule formation tracking utilizing DiI fluorescent labeling. Average area of large
nodule formations in DiI labeled samples for three material iterations. The 60-40 material film
iteration was not utilized due to observed unhealthy cellular activity.
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Figure 2.5. 80/20 material film seeded with MC 3T3-E1 cells and stained with Alizarin Red reagent.
Uptake of staining solution by nHA content of material presented as dark red generated large level
of background that prevented accurate assessment of cell mineralization.
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CHAPTER III:
IN VIVO BIOCOMPATIBILITY ASSESSMENT OF
POLYURETHANE/NANO-HYDROXYAPATITE FILM-DERIVED
OSTEOBIOLOGIC PLATFORMS USING A RAT UNICORTICAL
BONE DEFECT
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material through in vitro and in vivo experimentation was conducted at the
University of Tennessee in Knoxville. As such this chapter will address only the
biologic analyses and conclusions drawn from these data.

Abstract
The complex dynamic nature of bone tissue presents a unique challenge
for developing optimal biomaterials within the field of bone tissue engineering.
Materials based on biological and physiological characteristics of natural bone
have shown promise for inducing and promoting effective bone repair. Design of
multi-composite scaffolds that incorporate both malleable and hard mineral
components allow for intricate structures with nano- and macro-sized mineral
components to provide architectural elements that promote osteogenesis. The
examined scaffolds are multi-layered constructs differing only in the compositional
ratio of nano-hydroxyapatite (nHA) and decellularized bone particles (DBPs), and
incorporate previously studied nHA/polyurethane films interspersed with macrosized bone DBPs to stimulate integration with native tissue and induce osteogenic
activity.
In vitro assessment of cytocompatibility and osteo-stimulatory
characteristics indicated that the scaffolds did not negatively impact cell health and
demonstrated osteogenic effects. When the constructs were implanted in vivo, in
a rat tibial defect model, the biocompatibility and osteogenic impact were
confirmed. Futhermore, those treated with S-1 scaffolds exhibited greater levels
of new bone formation. These results indicate that, while both scaffold designs
were biocompatible, S-1 constructs demonstrate an optimal biologically relevant
nano-/macro- mineral architectural elements.
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Introduction
Design of an effective material for replacing and restoring function of
damaged bone has been an evasive and a complex challenge, which can be
attributed to the highly dynamic nature of the organ. As bone naturally possesses
self-regenerative ability, the main application of such materials will fall to cases
that exceed the inherent capabilities of this reparative mechanism (Deng et al.,
2008; Zhu et al., 2017; Kruyt Moyo et al., 2006). Currently, the most effective
treatment option utilizes autologous bone taken from a donor site of the individual.
This offers the ability to restore function without biocompatibility concerns yet relies
on a limited source and raises risk to the individual due to multiple surgical incisions
(Kruyt Moyo et al., 2006). To circumvent these restrictions, recent progress in
bone tissue engineering has turned to natural and synthetic scaffolds designed for
bone regeneration (Salgado, Coutinho, & Reis, 2004; Roseti et al., 2017).
Production of an ideal scaffold that can be readily synthesized, implanted, and
facilitate bone restoration similar, or superior, to an autograft offers an attractive
alternative. The optimal synthetic material should permit, or promote, existing
progenitor cells to integrate into the structure and provide a basal substrate for
natural remodeling to occur. Scaffolds fabricated using components derived from,
or similar to, those present in natural bone offer potential for inducing such
integrative properties without concern regarding biocompatibility. A bone tissue
regenerative scaffold should be composed of materials capable of osteoconduction and osseo-integration, as well as osteo-inductive potential when cells
or growth factors are delivered (Agrawal & Ray, 2001; Albrektsson & Johansson,
2001). Considering these characteristics, calcium-phosphate (CaP) ceramics are
one the commonly used “active” component within biomaterial constructs (Zhu et
al., 2017). Hydroxyapatite (HA), a widely investigated CaP, has pronounced osteoconductive capabilities and has demonstrated good biocompatibility within in vivo
environments, as well as indications of bioactivity in vitro (Zhu et al., 2017;
Habibovic et al., 2006; Kubasiewicz-Ross et al., 2017; Yu, Xia, Teramoto, & Ni,
2018; Fu et al., 2017; Fu et al., 2017). HA degradation may act to supply calcium
and phosphorous ions vital to new bone formation, and therefore acts to promote
osteogenesis in exposed cells (Fu et al., 2017).
Recent research in the field of material science, using both in vitro and in
vivo studies, has emphasized the importance of nano-biomaterial substitutes for
bone tissue engineering, as they may provide a more efficacious option compared
to their macro or micro sized counterparts (Christenson et al., 2007; Ha, Jang,
Nam, & Beck, 2015; Pujari-Palmer, 2016). Nano-biomaterials may present an
improved biological environment for facilitating osteo-inductive, osteo-conductive
and osseo-integrative functions. This is exemplified by the promise nanohydroxyapatite (nHA) has shown in stimulating osteogenesis, alone, or when it is
incorporated into matrix substrates (Liu et al., 2012; Ha, Jang, Nam, & Beck, 2015).
nHA particle deposition within material constructs can significantly influence the
topographical features of the surfaces of the material, such as enhanced surface
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area (Huang et al., 2004). However, increasing nHA content beyond a certain limit,
can lead to agglomeration and “chaotic” surface morphology, which can negatively
impact cellular activity. This indicates that tailoring of the nanocomposite surface
structures and roughness is vital to generating a material with optimal and
reproducible cellular growth and maturation (Danish et al., 2015). It has also been
suggested that incorporation of nHA into a material construct further enhances
adsorption of specific serum proteins due to high surface area/energy of
nanoparticles (Zhao et al., 2017; Mohsen-Nia, Massah Bidgoli, Behrashi, &
Mohsen Nia, 2012), which in turn promotes cellular adhesion to the substrate. The
porosity of such structures can also drastically impact efficient cellular ingrowth
and bone formation, with porosities ranging from 50-800 μm being optimal
(Unosson, Montufar, Engqvist, Ginebra, & Persson, 2016; Torstrick, Evans,
Stevens, Gall, & Guldberg, 2016; Chang et al., 2016; Hing, Best, Tanner, Bonfield,
& Revell, 2004). Therefore, by optimizing the combination of nano- and macrocomponents with specific physicochemical properties it is possible to develop a
nanocomposite capable of stimulating osteogenesis (Wang et al., 2018). Despite
the osteogenic potential, the in vivo toxicity of these nanomaterials should not be
disregarded, and hence, must be evaluated prior to clinical application.
We have previously reported that a 2D nanocomposite containing 80%
polyurethane (PU) and 20% nHA was cytocompatible and demonstrated a linear
increase in proliferation of MC3T3-E1 cells in vitro (Jackson et al., 2018).
Interestingly, the MC3T3E1 cells adhered to this composite in clusters and
appeared to form nodules which are considered as hallmarks of osteogenic
differentiation within 5 days of seeding and in the absence of any osteogenic
inducing reagents. Data suggested that the physical and chemical properties of
this nanocomposite seemed to present an ideal environment for cell adhesion,
proliferation, and osteogenic differentiation in vitro. Comparatively, a 2D
nanocomposite consisting of 90% PU and 10% nHA, despite lack of a linear
increase in cell proliferation, demonstrated cell-cell communication and clustering
similar to the 80% PU and 20% nHA composite25 and provided a comparative basal
element for design of a 3D construct.
In the present study, we synthesized a 3D scaffold containing a combination
of a carbon-based organic polymer, PU, and mineral components, nHA and
decellularized bone particles (DBPs) (Geistlich), in such a way that the resulting
scaffold consists of a complex nano-/macro-matrix with malleable and mineral
components. It has been suggested that for the human trabecular and cortical
bones taken together, the organic component ranges between 20-30% of the
mineral weight thus, a scaffold with a ratio of 1:2 – 1:4 of these components might
prove efficacious in bone healing and repair (Lees & Prostak, 1988; Yerramshetty
& Akkus, 2008; Raviraj Havaldar, 2012). PU, acting mechanically as a substitute
for the organic constituents in natural bone, is a biocompatible polymer which
provides the structure and flexibility to the scaffold. Incorporation of the inorganic,
mineral components, nHA and DBPs (nHA+DBPs) into this polymeric matrix
generates an environment compatible for integration with natural bone. nHA,
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provides the nano-content, is osteo-stimulatory and promotes an osteogenic
environment. The DBPs act as bioactive compounds to provide an osteoconductive macro-content to guide new bone formation. DBPs have been
demonstrated to have limited osteogenic potential alone and hence, are typically
complexed with other polymers to generate osteogenic scaffolds (De Santis et al.,
2017; DeNicolo et al., 2015). The resulting 3D scaffold is porous, pliable,
maintains structural integrity, and consists of nano- and macro-components which,
together, should generate an environment favorable to cellular migration and
osteogenesis (Huang et al., 2004).
We designed an in vivo rodent model to evaluate the osteo-conductive and
osseo-integrative nature of the scaffold, as well as determine biocompatibility.
Based on our in vitro results, and published information, we hypothesized that a
3D scaffold containing 80% PU / 20% nHA films with interspersed DBPs will be
biocompatible and will present an environment conducive for in vivo bone
regeneration. Our objectives were to fabricate and characterize a complex 3D
scaffold, assess this scaffold in vitro, and subsequently, evaluate its
biocompatibility and efficacy in vivo. To test our hypothesis, we first engineered,
manufactured, and characterized a 3D scaffold, verified cell adhesion, morphology
and cytocompatibility in vitro and, subsequently evaluated the osteogenic potential
and biocompatibility in vivo using a rat model with a unicortical tibial bone defect.
3D scaffolds comprised of 80% PU / 20% nHA material films interspersed with
DBPs, referred to as S-1, were evaluated alongside scaffolds comprised of 90%
PU / 10% nHA films interspersed with DBPs, referred to as S-2, to elucidate the
impact on the osteogenic environment of a scaffold due to variations in nano/macro-structural element compositions.

3D Scaffold In Vitro Analysis
Viability and Proliferation
Commercially obtained MC3T3-E1 cells were used for all in vitro assays as
described previously (Jackson et al., 2018). Cells were expanded in tissue culture
polystyrene flasks, at 37°C and 5% CO2 in αMEM media with 10% fetal bovine
serum and 1% penicillin streptomycin, which was replaced every 2-3 days. Cell
cultures reaching approximately 90% confluency were enzymatically released
from growth substrate using 0.25% Trypsin-EDTA solution for 2 minutes at 37°C,
collected, and allocated to tissue culture flasks or experimental set-ups. Cells
collected during passage were counted using a hemocytometer after 0.4% Trypan
Blue staining to ensure accurate seeding concentrations.
Individual plugs of both S-1 and S-2 were obtained from the bulk blocks (30
mm x 30 mm x 5 mm) using a 2mm biopsy punch. Each scaffold plug was placed
into individual wells of a non-tissue culture treated plate and exposed to growth
media for at least 1 hour prior to cell seeding. This was done to ensure scaffold
expansion and uniform exposure of material to media. Finally, the cells were
seeded to scaffolds with a seeding density of 5x105 cells/scaffold.
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Cell adhesion and morphology was confirmed in vitro on the 3D scaffolds
using previously described methods (Jackson et al., 2018). The commonly used
assessment techniques to measure cell proliferation and viability, including the use
of 3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTS) and the calcein-am and propidium iodide stains, could not be
used because of interference by the components of the 3D scaffolds. As a result,
cell adhesion and morphological changes were observed using the fluorescent
cytoplasmic stain, DiI. Since, DiI is retained in the cytoplasm of living cells, DiI
staining was also used to demonstrate cytocompatibility of the scaffolds. Cells
seeded on the S-1 and S-2 scaffolds were compared to cells cultured on tissueculture polystyrene dishes as positive controls, and to scaffolds in media alone
without cells, as negative controls.
In vitro evaluation of DiI stained MC3T3-E1 cells demonstrated that cells
adhered to the 3D scaffolds and exhibited clustering dynamics within 5-7 days of
seeding, suggesting osteogenic differentiation (Figure 3.1). Cell behavior was
similar to our observations on 2D PU/nHA films as described earlier (Jackson et
al., 2018). Cells adhered and formed clusters on the 3D scaffolds within 5 days of
seeding and in the absence of any differentiating reagents (dexamethasone, beta
glycerophosphate and ascorbic acid) (Jackson et al., 2018). Monitoring of cellular
morphology and proliferation through fluorescent microscopy demonstrated cell
adhesion and supports cytocompatibility of the materials. As this stain does not
effectively act as a means of assessing cytotoxicity, in vivo application was
necessary to demonstrate biocompatibility. Additionally, as described earlier, the
mineral components of the scaffolds prevented the use of alizarin red and alkaline
phosphatase staining, to demonstrate osteogenesis. Hence, morphological
observations and analysis of gene expression were used for in vitro evaluation of
scaffolds.
Based on the morphologic characteristics and cell-to-cell
communication observed at 5 days after cell seeding, all in vitro assays with the
3D scaffolds described in this study were carried out at this time point.
qPCR Assessment
We were unable to utilize Alizarin red and alkaline phosphatase assays
because of extensive interference from non-specific staining caused by the
presence of nHA. The background interference obscured the true values. As a
result, we used gene expression analysis of osteogenic markers to assess osteodifferentiation of cells.
Total RNAs were extracted from the cell/scaffold constructs 5 days post
seeding and analyzed for the expression of osteogenic-specific genes (Chou,
2005). Total RNA was isolated using the Trizol extraction agent (ThermoFisher)
as per the manufacturer’s protocol with certain modifications to increase the yield
of RNA (Lee, 2011). Briefly, all media was removed, and cell/scaffold constructs
were washed. 0.3 mL Trizol was added to each 2 mm scaffold and sonicated. An
additional 0.2 mL Trizol agent was applied post-sonication to inhibit the potential
entrapment of RNA by calcium precipitates from the scaffold material. Total RNA
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was further purified using RNeasy mini kit (Qiagen) and concentrations were
measured using a biophotometer. cDNA was prepared using a high-capacity
cDNA reverse transcription kit (Applied Biosystems). qPCR analysis of the
expression of the bone development markers osteopontin (OPN) and osteocalcin
(OCN) was carried out using SYBR green master mix (ThermoFisher) with GAPDH
serving as the housekeeping gene control (Agilent). Primer sequences and qPCR
conditions for each of the genes were as described earlier31. Relative fold
differences in the expression of osteogenic genes were calculated using ∆∆Ct
quantitation method (2008 Applied Biosystems). Averaged Ct values obtained
from MxPro PCR software for each sample per target gene were normalized using
GAPDH expression. Inclusion of blanks i.e. samples lacking template DNA,
allowed determination of maximum acceptable sample Ct values, with values
greater than 30 considered to be negative for the gene expression.
Total RNA extraction and purification, cDNA synthesis, and qPCR
conditions and analysis were all optimized using MC3T3-E1 cells differentiated on
polystyrene surface. MC3T3-E1 cells were differentiated in presence of the
osteogenic differentiation medium (growth media supplemented with 10 mM beta
glycerophosphate, 10 nM dexamethasone, 100 nM ascorbic acid) and the
expression profiles of OPN and OCN were evaluated after 7, 14, and 21 days post
induction. This was carried out to confirm osteogenesis and thus, the expression
of osteogenic-specific genes in MC3T3-E1 cells under conditions already
standardized on tissue culture polystyrene substrates in the absence of scaffolds.
MC3T3-E1 cells were cultured and differentiated towards osteogenesis on
tissue culture polystyrene substrates using standard protocols (Jackson et al.,
2018). As described earlier, these cells served as controls and ensured the
validation of RNA quality, cDNA synthesis, and real time PCR conditions for OPN
and OCN genes. The expression of the two osteogenic-specific gene markers was
evaluated in MC3T3-E1 cells after 7, 14, and 21 days in presence of differentiation
medium to confirm their osteogenic lineage. Using PCR conditions and the primer
sequences reported in Table 3.1, the expression profiles of OPN and OCN were
as expected during osteogenesis on tissue culture polystyrene substrates in the
absence of scaffolds. High mineral content of the scaffold constructs required
modifications of traditional extraction methods to improve yield and sample purity
(Lee, 2011). Total RNA from cell/scaffold constructs at 5 days, when cultured with
media having osteogenic-inducing agents, showed consistently poor yields and
low integrity. Therefore, total RNAs were isolated from the cell/scaffold constructs
only after 5 days post cell seeding in the absence of any differentiating media.
Real time PCR data demonstrating the expression of OPN and OCN genes
in cells seeded on the S-1 and S-2 scaffolds confirmed that the cells were indeed
of osteogenic lineage and that this was observed within 5 days of seeding and in
the absence of any differentiating reagents (Figure 3.2). When the expression of
these two genes was compared to cells that were differentiated on polystyrene
substrate, in the presence of osteogenic inducers for a period of 21-28 days
(Towler & Arnaud, 2002), there was a significant up-regulation of OPN expression,
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whereas the OCN expression did not change. OPN expression is associated with
early-stage bone remodeling processes, while OCN is more closely associated
with mineralization and late-stage bone development (Chou, 2005). The
significant up-regulation of OPN gene expression relative to cells differentiated on
polystyrene substrate for 21-28 days using osteogenic inducers may indicate an
enhanced degree of cellular remodeling within the scaffolds as this marker is
strongly correlated with osteoblastic activity. The lack of change observed in
expression of OCN at an early time point (day 5) may be due to the presence of
naïve bone cells, which have not matured to stages of bone mineralization and
ossification (Elkhenany et al., 2017). These late-stage processes are difficult to
achieve in static cultures for the short duration of 5 days.
The Ct values for cells seeded on both the scaffolds indicated that both
genes were expressed under the specified culture conditions, confirming that both
the S-1 and S-2 scaffolds attenuated osteogenesis spontaneously without any
induction, and within 5 days. Furthermore, comparison of expression between the
two scaffolds showed a significant up-regulation of both the OPN and OCN
expression when cells adhered and proliferated on S-1, thus, supporting a greater
osteogenic induction potential of S-1 relative to S-2.

3D Scaffold In Vivo Analysis
Tibial Defect Model
8-10-week-old Sprague Dawley rats were commercially obtained (Harlan
Laboratories). Animal procedures were performed in accordance with protocols
approved by the University of Tennessee, Institutional Animal Care and Use
Committee. An overview of the study design is depicted in Figure 3.3.
A unicortical, non-critical sized, defect of rat tibia was used as a model to
test the in vivo biocompatibility and osseointegration potential of the two scaffolds,
S-1 and S-2. Surgical procedures were carried out on four separate days to ensure
quality of the operative conditions, with equal numbers of sample groups per day.
Surgical procedures were as previously described (Elkhenany et al., 2017). Briefly,
under anesthesia, a 5 mm long incision was made above the tibial crest and the
periosteum was gently deflected to expose the bone surface. A uniform unicortical
defect was generated using a 3 mm burr (Stoelting). One tibia defect per animal
was treated with a scaffold, while the contralateral defect was left untreated to act
as a comparative control. This was alternated for every animal to randomize the
scaffold-treated tibia. Sites were closed with monofilament suture and animals
were monitored once daily for at least 7 days post-surgery to track incision site
appearance and overall animal health. 24 hours prior to sacrifice, animals were
given 20 mg/kg Oxytetracycline HCl subcutaneously (SQ) as a fluorescent bone
label. Animals were sacrificed 30 days after surgery.
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CT Analysis
After sacrifice, animals were scanned using computed tomography (CT) to
evaluate the defect sites. Animals were positioned in sternal recumbency on the
CT table with hind limbs fully extended to allow for optimal imaging of regions of
interest (ROI). Scanning parameters were limited to hind limbs and pelvis of each
animal. Files containing sectional scans and 3D renderings of ROI were collected
and analyzed by a board-certified radiologist, blinded to the sample groups.
Quantitative analysis of the area and density, and qualitative assessment of
periosteal reaction, sclerosis, swelling, mineralization, and gap healing of the
defect sites were obtained.
Quantitative and qualitative CT data were examined using SPSS statistical
software (IBM). Specifically, density and area measurements were assessed
utilizing Student’s t-test for significance. Periosteal reaction, sclerosis, swelling,
mineralization, and gap healing qualitative rankings were evaluated using the
Wilcoxon-Mann-Whitney test to determine significance for each characteristic
among study groups. Oxytetracycline fluorescence was compared using Student’s
t-test. For all data, P<0.05 was considered significant.
In vivo CT scans were obtained and analyzed to assess mineralization and
defect characteristics, 30 days post scaffold treatment. Analysis of cross-sectional
and 3D rendered images (Table 3.1, Figure 3.4) was conducted to produce
quantitative and qualitative data for the treated and untreated tibias of each animal.
Quantitative data, which included the area of the defect and density of the defect
tissue, were compiled and statistically analyzed. In this model of unicortical bone
defect of the tibia, the defects healed in both treated and the untreated control
bones.
Qualitative rankings for periosteal reaction, sclerosis, swelling,
mineralization, and gap healing at defect sites were assigned. All qualitative
rankings, except sclerosis, were statistically significant between both S-1 and S-2
treated defects and their respective untreated controls, with rankings for periosteal
reaction, swelling, and mineralization greater and gap healing lower in the scaffoldtreated defects. The enhanced mineralization could be attributed to late-stage
bone development for both S-1 and S-2 treated sites. These observations are
supported by in vitro findings of Chou et al. in which biomimetic apatite structures
stimulated a significant upregulation of OCN expression at 4 weeks. Increased
expression of OCN is closely correlated with ECM mineralization and may be
indicative of scaffolds facilitating osteoblastic maturation and osteo-conductive
capacities (Chou, 2005). Osteo-conduction, the ability of a scaffold to support
bone grows on (on-growth) or through (in-growth) the structure, is a vital
characteristic of an effective bone tissue regenerative scaffold. We used a noncritical sized bone defect to compare bone healing with and without the presence
of scaffold treatment. The lack of significant difference in area and density
measurements between treated and respective controls suggests that scaffolds
did not impair tissue repair and confirm that the scaffolds are biocompatible.
Despite variation present in qualitative rankings between treated and untreated
groups, these patterns were not abnormal and could be expected when a
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biomaterial or a scaffold is surgically implanted in vivo. Periosteal reaction and
swelling of tissue surrounding defect sites are commonly associated with surgical
implantation procedures (Shi, 2016; Yang, 2015; Bandyopadhyay, 2013), and, in
our study, do not pose concern of infection, as inflammatory agents were not
observed upon histological examination, further confirming the biocompatibility of
the scaffolds.
Histological Analysis
After CT, tibial sections were harvested and stored in 70% ethanol for
histomorphometry (Orthopaedic Histology and Histomorphometry Laboratory,
New Haven, CT). Undecalcified sections of 5 μm thickness were obtained for each
tibia. Sections from each bone sample were stained with Hematoxylin and Eosin
(H&E) and Toluidine Blue O. ImageJ software was used to generate mask
overlays of samples for quantitative assessment of H&E stained samples (Egan,
Brennan, & Pignolo, 2012; Stepan, 2002). Bone surface area in the defects were
first compared between the scaffold-treated with their respective untreated or
control groups. Subsequently, the treatments between the S-1 and S-2 scaffold
groups were evaluated.
Using both the H&E and Toluidine Blue stains, the orientation of the defect
was first established (Figures 3.5-3.7). All samples displayed healthy cellular
activity and formation of new bone matrix within defect site. Cellular activity
throughout the defect indicated that endogenous cell migration was not impeded
by scaffold implementation. Small regions of mineralization were detected, yet no
indication of inflammation or inflammatory agents were observed. Additionally, the
absence of inflammation, giant cell formation, and fibrous encapsulation further
supported the biocompatibility of scaffolds. The presence of osteoblasts,
osteoclasts and osteocytes within the defect further supported this biocompatibility
and indicated that scaffolds were capable of osseo-integration. Osseo-integration,
the stable anchorage and melding of a scaffold with native tissue, is an essential
characteristic for regenerative bone tissue technologies as permits the ability for
restoration of tissue function through direct bone-to-implant contact. Bone surface
area measurements from images of H&E stained samples using ImageJ software
showed lack of significant difference among treated groups and respective
untreated controls, as well as between the two scaffold-treated groups (Figure
3.8). This was not surprising and corroborated the CT findings (Table 3.1).
In vivo histological and CT observations (Figures 3.4, 3.6-3.8) for S-1 and
S-2 treated defects also appeared to compliment in vitro gene expression profiles.
Enhanced new bone formation in the S-1 treated tibias may indicate an increased
level of early-stage remodeling evidenced by an increase in OPN expression in
vitro, further suggests the osteo-conductive characteristics of this construct. The
presence of crystalline structures observed in the H&E staining and the increased
mineralization rankings in the CT analysis, predominantly associated with soft
tissue capping above the defect may represent a combination of remnants of
apatite crystals/DBPs (Shi, 2016) and newly mineralized bone in the scaffold
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treated samples. This enhanced mineralization could be attributed to late-stage
bone development for both S-1 and S-2 treated sites. These observations are
supported by in vitro findings of Chou et al. in which biomimetic apatite structures
stimulated a significant upregulation of OCN expression at 4 weeks. Increased
expression of OCN is closely correlated with ECM mineralization and may be
indicative of scaffolds facilitating osteoblastic maturation (Chou, 2005).
New Bone Analysis
The use of a bone fluorochrome, i.e. a bone label, known as Oxytetracycline
was used to evaluate new bone formation. For each tibia sample, total fluorescent
area of regions directly above, center, and the innermost area of the defect was
measured. Furthermore, three separate slides of each specimen were imaged,
and data was quantitated to develop a comprehensive fluorescent analysis.
Quantitation of Oxytetracycline fluorescent area in the ROI on unstained
histological sections was conducted with ImageJ software through generation of
binary masks for images, permitting measurement of fluorescent area relative to
total image area. Fluorescent areas expressed as a percentage of the total area
of images were averaged and statistical relations among groups were obtained.
Fluorescent values for both the S-1 and S-2 treated samples were first compared
to their respective untreated control samples, and subsequently to each other.
Oxytetracycline SQ injections given to rats 24 hours prior to sacrifice offer
a mechanism for analyzing relative formation of new bone between the treated and
untreated tibias at that time point because it binds to the newly deposited calcium
(Nkenke, 2002). The antibiotic fluoresces with an emission wavelength of 512 nm
when excited by a wavelength of 390 nm. As the fluorescent compound is strictly
excluded from bone except during bone formation, areas exhibiting fluorescence
can be strongly correlated to regions of new bone activity (Blair et al., 2017).
Imaging followed by the quantitation of the oxytetracycline fluorescence, showed
that the S-1 treated tibias demonstrated significantly higher fluorescence
compared to both the respective untreated group and the S-2 treated samples
(Figures 3.9-3.10). The lack of significance between the untreated control groups
supported the validity of the bone model used in this study.
The significant increase in fluorescent readings for S-1 represent enhanced
new bone formation in defects treated with this scaffold as compared to untreated
controls and defects treated with S-2. Given that the primary variation in structural
design between the nanocomposites resides in the compositional nHA level, the
significant increase in new bone formation for S-1 treated defect sites can be
attributed to the 10% greater nHA content of basal PU-nHA films as compared to
S-2. As nHA has been shown to demonstrate bioactive characteristics, the
enhanced incorporation of nHA coupled with the conserved presence of DBPs,
which offer macro structures to support cellular interaction, may provide a superior
biological environment for recruitment of endogenous cells. The high adsorption
capacity of nHA may be a driving factor for cellular migration and activity (MohsenNia, Massah Bidgoli, Behrashi, & Mohsen Nia, 2012); however, this can also lead
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to particle agglomeration and formation of chaotic surface structures (Fu et al.,
2017), and hence, the concentration of nHA seems to be critical. S-1 appears to
demonstrate an optimal balance of compositional nHA, producing an effective and
biocompatible environment for bone repair with both osteo-conductive and osseointegrative capacities.
These results combined with those from previously described in vitro and in
vivo studies suggest that, while scaffolds containing nano- (nHA) and macro-sized
(DBPs) components bound with a polymeric matrix (PU) do provide a stable
platform for tissue regeneration, cell behavior is significantly different between S1 and S-2, despite compositional dynamics being similar. We conclude that S-1
demonstrated the most significant findings with regards to early-stage remodeling
gene expression (in vitro) and new bone formation (in vivo). This indicated that, in
addition to the biocompatibility exhibited by both scaffold iterations, S-1 also offers
modulative effects on exposed cells. CT analysis of S-1 treated defects
demonstrated that material did not elicit any abnormal tissue reaction above what
would be expected from implantation of a novel biomaterial, and the mineralized
regions seem to correspond to the presence of bone particles in scaffold, though
it may also be an evidence of late-stage bone development from induced cells.
The success of a 3D bone tissue engineering scaffold is largely dependent
on efficient cell seeding, proliferation, viability, distribution and infiltration. In vitro,
when cells are seeded onto a newly synthesized 3D bone tissue engineering
scaffold, we expect the cells to be viable, proliferate, spread uniformly, and
undergo osteogenesis, thereby demonstrating the cytocompatability of the
scaffold.
Fluorescent staining confirmed cell adhesion, clustering and
cytocompatibility. Additionally, we were able to evaluate the osteogenic nature of
MC3T3-E1 cells by demonstrating the expression of two important and commonly
used osteogenic genes, OPN and OCN by real time PCR. The in vitro results gave
us the confidence to implant the scaffolds in vivo and to establish the
biocompatibility and the osteoconductive potential of the platform. With this focus,
we used a relatively simple biocompatibility rat model utilizing a unicortical defect
in the tibia. The significant differences detected between the two scaffolds using
the bone fluorochrome, supported confidence of both the model and the study
design. Furthermore, DAPI staining of histological sections verified cellular
migration into the material, as nuclei were detected throughout scaffold treated
defects (Figure 3.11). Utilizing this combination of in vitro and in vivo strategies,
we proved our hypothesis and demonstrated that the scaffolds were biocompatible
with one scaffold displaying an osteogenic effect. Future experiments will involve
testing the scaffold S-1 in segmental defect models where mechanical integrity of
newly formed bone can be assessed.
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Conclusion
The designed synthetic scaffolds are intended to provide a supportive and
modulatory environment for endogenous cells to enhance bone repair. In vitro and
in vivo assessment of scaffolds appeared to confirm that both material iterations,
primarily S-1, were biocompatible and displayed key attributes for a bone graft
biomaterial. Significant new bone formation in S-1 treated defects demonstrated
that this combination of PU with both nano- (nHA) and macro-sized (DBPs)
components, was optimal for generating a biocompatible environment that is both
osteo-conductive and osseo-integrative. From these findings, the S-1 construct
shows great potential as an effective substitute graft material for damaged/injured
bone, and warrants continued investigation utilizing models that may more
appropriately simulate common injuries observed in human medicine.
An additional in vivo assessment utilizing this tibial model was conducted to
compare both the S-1 and S-2 iterations with scaffolds constructed using the 70/30
and 60/40 PU-nHA films discussed in the earlier chapter. This was done to confirm
that the S-1 scaffold maintained preferable characteristics to these constructs as
in the case of their respective films. In an attempt to avoid the degree of
spontaneous healing observed in the previous in vivo evaluation, the time frame
of this study was reduced from 30 to 15 days. Results from this analysis yielded
largely similar data with regards to S-1 and S-2 treated groups. Interestingly,
defects treated with scaffolds derived from 70/30 and 60/40 films exhibited
substantial fluorescence intensities; however, histological assessment revealed
large crystalline mineral structures throughout these treated defects (Figure 3.12).
These regions also appeared to be responsible for the high fluorescence intensity.
Based on these findings it was determined that, despite fluorescence intensity
values, the scaffolds derived from these films were not suitable for in vivo
application. As this study verified that the S-1 scaffold maintained preferable
characteristics to other iterations, this nanocomposite would be the primary
candidate for continued assessment.
To further examine the efficacy of S-1 as a bone graft substitute material as
well as its potential for application in the field of craniomaxillofacial surgery, the
material was subject to another rodent in vivo study. For this assessment a 5mm
mandibular defect model was utilized to observe the capacity of the scaffold to
integrate with surrounding native tissue and to facilitate tissue development
throughout the construct matrix. In place of the void defects used in the previous
in vivo tibial defect model, two predicate devices were implemented to permit
comparison of the test article to current commercially available products.
Additionally, another iteration of the scaffold fabricated with a modified method was
tested evaluate if the new fabrication method would enhance or alter the biological
functionality of the material. Verification of biocompatibility and osteogenic
capacity via this mandibular model would serve to concrete function of the material
within a complex system, while also circumventing some of the limitations
observed in the unicortical tibial model, primarily defect parameter consistency and
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spontaneous defect closure. This work and resulting data are detailed in the
following chapter.
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Appendix

Figure 3.1. Day 7 DiI imaging of MC 3T3-E1 cells on 3D scaffold. Representative images depicting
DiI-labeled cells 7 days post-seeding to S-1 cultured in media with and without osteo-differentiation
inducing agents (a and b) and to S-2 cultured in media with and without osteo-differentiation
inducing agents (c and d).
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Figure 3.2. Gene expression of S-1 and S-2 treated cells cultures. PCR fold differences for OCN
(a) and OPN (b) expression in S-1 and S-2 exposed cell cultures as compared to cultures on
polystyrene surfaces in presence of the osteogenic differentiation reagents for 28 days. Gene
expression was normalized with GAPDH expression
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Figure 3.3. In vivo model timeline. Major study checkpoints of in vivo assessment of scaffold are
indicated by branches, and time point objectives are detailed by bulleted lists. The studied sample
groups include the S-1 (n=10) and S-2 (n=10) scaffold treated and untreated limbs (n=20).
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Table 3.1. CT qualitative and quantitative statistical analysis. Assessment of qualitative CT scoring
utilized non-parametric Wilcoxon-Mann-Whitney statistical test (Top). Exact significance values
display significant differences among sample groups. Assessment of quantitative CT values for
area and density utilized parametric Student’s t-test (Bottom). P-values were considered significant
if <0.05. The studied sample groups include S-1 treated (n=10), S-1 untreated (n=10), S-2 treated
(n=10), and S-2 untreated (n=10).
Wilcoxon-Mann-Whitney

Periosteal

Sclerosis

Swelling

Mineralization

Gap Healing

S-1 Treated/Untreated (p-value)

0.143

0.165

<0.005

<0.005

0.011

S-2 Treated/Untreated (p-value)

0.052

0.280

0.001

0.001

0.023

S-1/S-2 Treated (p-value)

0.315

0.353

1.000

0.739

0.393

Student’s t-test

Area (mm²)

Density (HU)

S-1 Treated/Untreated (p-value)

0.481

0.057

S-2 Treated/Untreated (p-value)

0.081

0.321

S-1/S-2 Treated (p-value)

0.168

0.273
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Figure 3.4. S-1 and S-2 untreated/treated defect CT imaging. Representative images depicting
CT 3D rendered model for S-1 (a and c) and S-2 (e and g) groups and cross-sectional for S-1 (b
and d) and S-2 (f and h) groups. Untreated (a,b,e,f) and treated (c,d,g,h) sample (n=10). The
callus formation observed in the S-2 treated limb (g) indicates an increased mineralization due to
material exposure.
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Figure 3.5. Defect orientation for histological imaging.
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Figure 3.6. H&E imaging of S-1 and S-2 treated and untreated defects. Representative images
depicting H&E stained histological sections from S-1 untreated (n=7) and treated (n=7) samples
(a-b, e-f) and S-2 untreated (n=6) and treated (n=6) samples (c-d, g-h). Images displaying defect
are at 5x (a,c,e,g) and 10x (b,d,f,h) magnifications.
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Figure 3.7. Toluidine Blue imaging of S-1 and S-2 treated and untreated defects. Representative
images depicting Toluidine Blue O stained histological sections from S-1 untreated (n=7) and
treated (n=7) samples (a and b) and S-1 untreated (n=6) and treated (n=6) samples (c and d).
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Figure 3.8. H&E-based bone surface area measurements. Percent area coverage data from
ImageJ generated binary masks of H&E stained samples.
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Figure 3.9. Oxytet fluorescence imaging of S-1 and S-2 treated and untreated defects.
Representative images depicting Oxytet fluorescence of unstained histological slides for S-1
untreated (n=8) and treated (n=8) samples (a and b), and S-2 untreated (n=9) and treated (n=9)
samples (c and d).
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Figure 3.10. Fluorescent area analysis. Oxytet average fluorescent area data comparing treated
and untreated groups for S-1 and S-2 constructs. Total fluorescent area derived from averaging of
regions of interest directly above, center of, and innermost area of defects. Sample size displayed
below respective groups.
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Figure 3.11. DAPI fluorescence imaging of S-1 and S-2 treated and untreated defects.
Representative images depicting fluorescence of histological slides stained with DAPI for
visualization of cell nuclei within defect. S-1 untreated (n=8) and treated (n=8) samples (a and b)
and S-2 untreated (n=9) and treated (n=9) samples (c and d) are shown. DAPI detection within
scaffold treated defects indicates cellular migration into material.
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Figure 3.12. Oxytet fluorescence imaging of defects treated with scaffolds derived from 70/30 and
60/40 PU-nHA films. Representative images depicting Oxytet fluorescence of unstained
histological slides demonstrate large crystalline mineral structures present in these treated defects.
Images have been left as black and white fluorescent camera captures to emphasize crystalline
strucutres.
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CHAPTER IV:
IN VIVO COMPARISON OF OSTEOBIOLOGIC PLATFORMS WITH
PREDICATE DEVICES USING A RAT CRITICALLY-SIZE BONE
DEFECT
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Abstract
The development of effective bone graft substitute biomaterials has been a
critical pursuit in addressing the demand for alternatives to autogenous bone that
are both cost effective and readily synthesized. This challenge is further
complicated in the treatments associated with oral/maxillofacial injuries due to the
complex anatomical nature of flat bone. As a result, a wide assortment of
biomaterial designs has been implemented with varying effect characteristics and
magnitudes, stemming from differences in physical and chemical properties of the
matrix. Therefore, it is essential to develop assessment techniques to objectively
compare new osteogenic platforms with existing medical technologies that have
well-documented effects. This study examines a previously reported layer-bylayer synthesized nanocomposite, comprised of polyurethane (PU)/nanohydroxyapatite (nHA) films interspersed with bovine-derived decellularized bone
particles, as well as a variation employing a modified synthesis method. Utilizing
a 5mm mandibular defect model in rats, these two scaffold iterations were tested
in vivo for their osseo-integrative capacity and ability to facilitate new bone
formation within the defect site as compared to multiple predicate devices. BioOss
Collagen® (Geistlich), a xenograft comprised of decellularized bovine bone
particles and porcine collagen, and Syntoss® (Dental Solutions Isreal), a synthetic
graft comprised of β-tricalcium phosphate (β-TCP) and hydroxyapatite (HA), were
used as predicate groups. Rats were randomly divided into 4 treatment groups
and the mandibular defects in each group were treated with one of the four
composite materials. Rats were sacrificed and subjected to computed tomography
(CT) at 30- and 60-days post-treatment. Ultimately, the flat bones were harvested
and subjected to histomorphometric analyses. Histological sections were stained
with H&E and Masson’s trichrome for tissue analysis. Unstained sections were
used for immunohistochemical evaluation. Quantitative and qualitative CT data
provided by a certified radiologist indicated that the two nanocomposites were not
significantly different from the predicate devices. Histological assessment utilizing
ImageJ software for the Masson’s trichrome stain indicated a significantly
enhanced level of collagen and early bone formation in defects treated with the
modified synthesis method nanocomposite. Additionally, observational analysis of
stained sections appeared to demonstrate effective osseo-integrative capacities of
both the nanocomposites. Immunohistochemistry (IHC) of samples furthermore
established the presence of the hematopoietic stem cell marker, CD34, within the
defect region of specimens treated with the experimental materials. These findings
suggest that, though both examined nano-composites display biocompatible and
osseo-integrative characteristics comparable to common predicate devices, the
iteration utilizing a modified synthesis method may offer an effective and superior
design for an osteogenic platform.
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Introduction
The development of effective biomaterials for repairing and restoring
functionality of bony defects has remained a major area of research within the field
of regenerative medicine. This is largely due to the complex and dynamic nature
of native bone, which undergoes constant remodeling through osteoblastic and
osteoclastic functions. Though the regular restructuring activity of these processes
are capable of repairing minor tissue injuries, damage to tissue that exceeds
natural repair limitations necessitate application of a grafting material that can
facilitate and promote regeneration of the defect (Zhu et al., 2017). However, the
inherent hierarchical architecture of native bone complicates design of an optimal
bone graft substitute material. Comprised of an intricate matrix of organic and
inorganic elements in both nano- and macro-structural configurations, the tissue
presents unique challenges to bio-mimicry of the mechanical and biological
environment (Thula et al., 2011). The current gold standard for repair of these
defects, therefore, remains the use of autologous bone grafts, tissue collected from
a donor site of the individual receiving treatment. Despite the highly effective
nature of autografts, the requirement of multiple surgery sites and the potential for
donor site morbidity pose risks to patients. Therefore, a wide variety of grafts
derived from allogenic, xenogeneic, and synthetic origins have been implemented
with the goal of achieving similar or superior reparative characteristics (Salgado et
al., 2004; Sheikh et al., 2017).
A noted high degree of variability has been observed in the processing
methods utilized by different material developers for biologically-based grafts,
those from allogenic and xenogeneic origin. This can be observed in the wide
array of protocols employed for decellularizing, which is the elimination of organic
components to isolate the inorganic/mineral construct, source tissue, resulting in
varying degrees of residual organic compounds. This in turn may substantially
dictate the ability of a material to integrate within native tissue and promote repair
(Saulacic et al., 2015). This inconsistency among these biologically-derived bone
graft products has further driven demand for synthetic scaffold designs that utilize
simple manufacturing methods and readily available compositional elements.
These composites generally attempt to resemble aspects of native bone either in
chemical composition, for example similar mineral content, or in physical attributes,
such as porosity and tensile/compression dynamics. Some of the most common
compositional additives are hydroxyapatite (HA) and beta-tricalcium phosphate (βTCP), which are both mineral compounds that resemble formations within native
bone and maintain osteo-conductive functions (Sohn et al., 2018; Gorla et al.,
2015; Ramalingam et al., 2016). Other graft designs have implemented more
organic components, such as collagen or osteo-related growth factors, to serve
bio-active functions post-implantation (Kim et al., 2015; Sun et al., 2014).
Recently, application of nano-scale particles in combination with marcoscale scaffold architecture has demonstrated promise in generating integrative
cellular environments. Particularly, the use of nano-hydroxyapatite (nHA) particles
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offer potential as an osteo-inductive component, capable of inducing native
progenitor cells toward a bone cell lineage, and serve to promote cell migration
and tissue in-growth through rapid adsorption of serum proteins (Mohsen-Nia et
al., 2012; Jackson et al., 2018; Bow et al., 2019). Combining such components
with other bio-active materials and incorporating these into a polymeric matrix
allows for production of biologically effective scaffolds that maintain ideal
mechanical properties. A previously examined scaffold that encompasses this
scaffold design strategy is comprised of a mix of nHA and decellularized bone
particles (DBPs) dispersed within a degradable polyurethane matrix (Bow et al.,
2019). The present study intends to further evaluate this composite that is
synthesized using a layer-by-layer method, as well as a variant design that
employs a salt-leeching technique to form scaffold pores.
Apart from design and development of scaffolds, increased importance is
being attributed to the selection of appropriate evaluation techniques. Particularly
for in vivo assessment of test articles, the selection of a suitable model is critical
and will be largely dependent on the intended application for the graft material, i.e
oromaxillofacial or long bone repair (Bigham et al., 2015). Rodent models serve
as a well-established means of examining treatment methods with minimal animal
to animal variance, allowing for implementation of necessary control groups. A
mandibular model described by Higuchi et al. (1999) offers the potential to assess
material graft designs in a consistently-sized circular defect in flat bone, which
should be indicative of a graft’s effectiveness in oromaxillofacial operations. As
discussed in Tatara et al. (2016), the current standard treatment for a criticallysized mandibular injury is the use of a free fibular flap, which involves transplanting
a segment of the patient’s fibular with native vasculature at the defect site. As
mentioned previously, such treatments, though effective, result in increased risk to
the patient, thereby stimulating development of substitute grafting materials. As
defect sizes within this mandibular model exceeding 3mm are considered to be
“critically-sized”, the implementation of a 5mm dimeter defect will permit
assessment of the ability of treatment materials to facilitate repair and restoration
of tissue that has been damaged beyond its natural reparative capacity (Kustro et
al., 2018). The present study evaluates two test articles with similar compositions
as compared with reparative capacity of two currently commercially available and
commonly utilized scaffolds, BioOss Collagen® and Syntoss®. The conducted
comparative analysis with predicate devices permits an efficient and relevant
evaluative technique for development of optimized graft materials.

Examined Graft Materials
Experimental Materials
The previously assessed 3D osteogenic platform designated as S-1 was
utilized in this study to further examine its effectiveness in repair of a 5mm
mandibular defect as compared to current predicate devices (Bow et al., 2019).
Additionally, an iteration of this scaffold design implementing a modified fabrication
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method was included in this comparative material assessment. The S-1 scaffold,
as described in the previous chapter, utilized a layer-by-layer manufacturing
technique, while the modified design, designated M-1, was constructed through a
salt-subtraction method. Both S-1 and M-1 are composed primarily of nanohydroxyapatite (nHA) and decellularized bone particles (Sigma-Graft), with a
degradable polyurethane (PU) as a binder.
Predicate Materials
Produced and distributed by Geistlich, BioOss Collagen® is a composite of
deproteinized cancellous bone particulate product of bovine origin and 10%
porcine collagen fiber.
BioOss Collagen® has demonstrated significant
enhancement of new bone development when implemented in non-weightbearing
bony defects, particularly when incorporated as a supportive element to
autologous bone particulate (Aludden et al., 2017; Araujo et al., 2010; Lee et al.,
2014).
Syntoss® is a synthetic bone graft substitute comprised of 60% β-TCP and
40% HA that is produced and distributed by Dental Solutions Israel. Similar to
characteristics of the previously described synthetic grafting materials, this product
maintains strong biocompatibility and osteo-conductivity, largely due to the high
mineral content and porous structure. As per product site, Syntoss® grafts are
capable of ionic release of Ca and phosphate ions that can stimulate native tissue
to enhance osseo-integration.

In Vivo Graft Comparative Analysis
Mandibular Defect Model
Sprague Dawley rats were received and maintained at facilities for 7 days
prior to surgeries for acclimation.
Pre-surgical analgesic application of
buprenorphine was administered, and animals were anesthetized with isoflurane
delivered via inhalation for the duration of the surgery. Sterile prep of the surgery
site was performed through removal of hair and application of 70% ethanol,
chlorohexidine, and betadine solutions respectively. Surgical operations were
then carried out. Briefly, a linear incision through epidermal and subcutaneous
tissues was made to expose the lower portion of the masseter muscle. A single
incision was then made through the masseter muscle using the parotid duct as a
guide parameter to expose the mandibular ramus and angle of the mandible.
Utilizing a trephine drill bit, a 5mm circular defect was generated on this surface
with the ridge of the mandibular ramus as a guide parameter to maintain
consistency of defect location. Resulting defect void space was then filled with
treatment material cut to appropriate size. Treatment groups consisted of two test
materials with similar composition but varied synthesis procedures and two
predicate materials, BioOss Collagen® and Syntoss®, acting as controls. Postimplantation, sites were closed through initial suturing of muscle layer and then of
subcutaneous tissue. Animals were monitored closely to verify recovery and then
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transferred to housing room. Regular monitoring of animals was then carried out
for 1 and 2-months post-operation with primary diet of soft gel food for the first 2
weeks before switching to standard dry pellet diet. At 1 and 2-month postoperation time points animals were sacrificed as per protocol and CT scans of
region of interest were taken. Treated mandibles were then harvested from
specimens for histological sectioning and staining, with tissue stored prior to
sectioning in Decal A solution.
CT Analysis
CT scans were performed on animals after sacrificed at 1 and 2-month postoperation time points. 3D renders were generated and collected scans were
evaluated by a certified radiologist for both quantitative and qualitative parameters.
Measurements for area and density comprised the quantitative element and were
coupled with a set of qualitative characteristics developed and employed in a
previous study. These parameters include subjective rankings of 0 (negligible) to
3 (severe) for periosteal reaction, sclerosis, swelling, and mineralization, as well
as healing with scores ranging from 0 (no closure) to 3 (completely healed).
CT imaging verified that defect generation was successful, and materials
persist within the site (Figure 4.1). Early tissue formation was observed
throughout defect sites treated with both test materials, with possible indication of
new bone formation. Quantitative results for area and density were averaged
within groups to generate comparative values. Area data for test materials at both
time points showed no statistically significant variation from each other.
Additionally, test materials did not appear to differ substantially from values of
exhibited by predicate materials at respective time points (Figure 4.2). Density
data did demonstrate significant variation among groups; however, this was
expected due to the observed mineral content difference between test and
predicate materials. This is illustrated particularly well in the enhanced density
measurement of Syntoss® samples, designated S1 and S2 in Figure 4.2, which
can be correlated to the dense mineral content of the β-TCP/HA matrix.
Histological Analysis
Histological sections were cut from paraffin-embedded decalcified tissue
samples at 1-5um thickness. Sets of sections included one slide stained with H&E
for general cellular reaction assessment, one slide stained with Masson’s
Trichrome for evaluation of present tissue types, and 3-5 unstained slides for
immunohistochemistry (IHC). Masson’s Trichrome stained slides were used to
generate semi-quantitative data for new early collagen/bone tissue surface area.
Captured images were processed through ImageJ software to create binary masks
highlighting tissue of interest, which were subsequently measured as a ratio of
highlighted area to total area (Schindelin et al., 2012).
Gross evaluation of H&E stained sections showed an absence of
inflammatory signs indicating that all materials were biocompatible. Preliminary
Masson’s Trichrome imaging resulted in observational differences in tissue content
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within the defect (Figures 4.3-4.6), and therefore necessitated further assessment
via ImageJ software. Semi-quantitative data for early collagen/bone formation
surface area demonstrated that test materials exhibited significant increase in
surface area from 1-month to 2-month time points. Additionally, one test material,
designated as M-1 in Figure 4.7, was found have significantly enhanced surface
area as compared to all other material types by the 2-month time point.
Immunohistochemistry Analysis
Unstained histological sections of test article samples were subjected to
deparaffinization using xylenes and prepped for immune-staining to determine
presence and intensity of specific proteins related to angiogenesis, cell
attachment, and bone formation. Prepped samples received primary antibodies
for the marker of interest, which were then subjected to a biotinylated secondary
antibody. A tertiary staining solution conjugated with an avidin-horseradish
peroxidase (HRP) molecule capable of strong binding with biotin was utilized to
permit detection through a Nova Red staining kit. For contrasting target protein
stain during high magnification imaging, hematoxylin staining was implemented,
which presents as a blue stain localized to the cell nuclei. An overview of this IHC
protocol can be observed in Figure 4.8.
Preliminary imaging of IHC stained sections showed promise in detecting
specific markers within sample tissue. M-1 and S-1 treated 2-month sections
stained for cell attachment and osteo-related markers, including osteopontin
(OPN), Sp7, CD34, and fibronectin (FN), demonstrated positive detection and
were compared observationally for distribution and organization of protein
expression (Figures 4.9-4.12).

Conclusion
Examination of H&E stained slides demonstrated that the test articles and
the comparative predicate devices were biocompatible with the surrounding native
tissue. This was consistent with previously published data evaluating the Scaf-B,
which utilized the layer-by-layer synthesis method, and with expectation for the
Scaf-K experimental article based on the similar composition. As the two
implemented predicate devices are commercially available products for use in
oromaxillofacial surgery, and therefore were not anticipated to induce any
biocompatibility complications. At 1-month post-implantation, samples for all
treatment groups did not display significant differences for area or early
collagen/bone formation values indicating that the materials maintained similar
reparative characteristics at this time point. However, as evident in stained
sections, both H&E and Masson’s Trichrome, of the Syntoss® treated defects,
there was a notable reduction in the level of tissue in-growth to the injury site as
compared with other treatment groups. This reduced tissue in-growth is
pronounced in 2-month samples as compared with other treatments and resulted
in a significantly lower surface area coverage by early collagen/bone tissue, as
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observed in Figure 4.7. Apart from Syntoss®, all treatment groups appeared to
demonstrate similar tissue in-growth through gross histologic observation and no
statistical differences were detected within the 2-month time point samples.
Substantial variation among groups in density analysis of CT data was determined
to more closely correlate with the initial material mineral content, which is
exemplified by the Syntoss® material at both time points, as opposed to new bone
formation. The comparable regenerative capacity between experimental materials
and BOC, as observed in quantitative and observation data, gives strong indication
that the test articles are capable of generating an effective osteogenic
environment.
To further assess this, IHC of bio-markers targeting osteogenic, cell
attachment, and angiogenic elements was employed. As the primary purpose of
this assessment was to observe the presence, distribution, and organization of
these select proteins in defects treated with the test articles, focus was place on
examining 2-month samples treated with these scaffolds only. Prominent
detection of the osteo-related transcription factor, Sp7 (Osterix), and the early bone
formation marker, OPN, strongly supported the ability of the test articles to facilitate
both osteo-conductive and osteo-inductive functions (Kague et al., 2016). Sp7 is
one of the primary regulating factors for osteogenic differentiation of cells along
with the RUNX2 and stimulates the upregulation of key osteo-associated proteins
including bone sialoprotein (BSP), osteocalcin (OCN), osteonectin (ON), and OPN
(Rahman et al., 2015; Pinero et al., 1995). Detection of this transcription factor in
defects treated with both test articles therefore illustrates the osteobiologic
capacity of the scaffold technologies. However, while this protein was observed
through-out the defects, it appeared more concentrated in tissue immediately
surrounding structures determined to be remaining DBPs, which indicates that
these sites may possess strong osteo-inductive properties. OPN, which is key cell
attachment protein in bone and synthesized by preosteoblasts, osteoblasts, and
osteocytes, demonstrated prolific presence within and surrounding the defect
region, with distribution forming concentric rings that appeared to emanate from
the center of the defect (Butler, 1989). These well-defined fronts are characteristic
of OPN, which is concentrated at cement lines, and represent potential bone
formation fronts, as it operates as a critical matrix organization protein in concert
with OCN (Singh et al., 2018; Blair et al., 2017; Foster et al., 2018). Regions
stained for OPN resemble those stained for FN in pattern and organization,
demonstrating that both proteins play crucial roles in coordinating cell attachment
and matrix organization throughout the defect (Brown et al., 1992). FN has been
shown to have a major role in the formation and organization of extracellular matrix
and cell to cell communication networks, particularly within craniomaxillofacial
tissue repair (Al-Qattan et al., 2014; Kim et al., 2015), so the strong intensity of
protein in stained samples indicates cellular communication both within the
scaffold treated defect and at the scaffold-native bone interface, which further
supports the osteo-integrative capacity of the nanocomposites. In addition to these
osteogenic and cell attachment proteins, prominent detection was observed for the
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transmembrane protein CD34, which is associated with hematopoietic stem cells,
enhanced progenitor activity, and early vasculature development (Sidney et al.,
2014). Furthermore, cells positive for this surface protein are capable of facilitating
environments that promote both angiogenesis and osteogenesis, as they maintain
the potential to differentiate to both endothelial and osteoblastic cells (Kuroda et
al., 2014). Therefore, the expression of CD34 throughout defects treated with both
scaffold iterations demonstrate healthy reparative function. As in the case of Sp7
stained samples, CD34 appears to be most prolific surrounding residual DBPs
within the scaffold matrix, which further indicates that these particles may serve as
stimulatory surfaces for osteogenic differentiation and new tissue development.
Notably, the expression of both Sp7 and CD34 appear to be more organized and
pronounced in the samples treated with the modified fabrication method scaffold,
which may be due to a more uniform distribution of construct contents.
The detection of these crucial proteins throughout scaffold treated defects,
in addition to the enhanced levels of early collagen/bone formation in M-1 treated
defects as determined by evaluation of Masson’s trichrome stained samples,
indicates that this scaffold material utilizing the modified fabrication method is
capable of providing an effective osteogenic platform. As such the mechanisms
responsible for the observed osteogenic capacity of the bone graft material were
of great interest and will be explored in a later chapter. The effective nature of this
osteobiologic scaffold encouraged the development of relatively advanced graft
materials for more specialized applications that utilized similar compositional
elements. These materials included an injectable gelling material with nHA
incorporated and a super-hydratable variant of the M-1 scaffold capable of
substantial swelling when wetted. Similar assessment methods were used as in
the mandibular defect model to assess early collagen/bone formation surfaces and
determined the presence of key proteins associated with osteogenic and cell
attachment functions. As the primary purpose of these studies was to evaluate the
biocompatibility of these advanced materials, the previously described rodent
unicortical defect model was used. Additionally, this model was necessary as
compared to the mandibular model due to the nature of the injectable material,
which would be challenging to maintain at the defect site. The super-hydratable
scaffold, being comprised of similar materials to S-1 and M-1 iterations, was
anticipated to be cytocompatible and therefore was only subjected to a brief DiI
staining assessment in vitro verify similar morphological characteristics to
previously examined scaffolds. However, further in vitro work was required for the
injectable material as the basal components varied from previously assessed
grafts. The in vitro, and subsequent in vivo, evaluation of these advanced
materials is encompassed in the following chapter.
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Appendix

Figure 4.1. Mandibular defect model CT 3D renders. Test articles designated M-1 (a & b) and S1 (c & d) at as compared with predicate materials, BioOss Collagen® (e & f) and Syntoss® (g & h)
at 1-month and 2-month time points respectively.
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Figure 4.2. Graphical representation of mandibular CT area (a) and density (b) data. Test articles,
M-1 (K) and S-1 (B), and predicate materials, BioOss Collagen® (BOC) and Syntoss® (S), are
shown. Numerical designation following letter code indicates study time point, either 1-month (1)
or 2-month (2).
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Figure 4.3. Masson’s Trichrome images of M-1 at 1 and 2 months after implantation. Full defect
region (a & d) derived from stitched 5x images and magnified regions depicting the defect border
(b & e) and center (c & f) are shown.
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Figure 4.4. Masson’s Trichrome images of Bio-Oss Collagen® at 1 and 2 months after
implantation. Full defect region (a & d) derived from stitched 5x images and magnified regions
depicting the defect border (b & e) and center (c & f) are shown.
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Figure 4.5. Masson’s Trichrome images of Syntoss ® at 1 and 2 months after implantation. Full
defect region (a & d) derived from stitched 5x images and magnified regions depicting the defect
border (b & e) and center (c & f) are shown.
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Figure 4.6. Masson’s Trichrome images of S-1 at 1 and 2 months after implantation. Full defect
region (a & d) derived from stitched 5x images and magnified regions depicting the defect border
(b & e) and center (c & f) are shown.
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Figure 4.7. Graphical representation of early collagen/bone formation surface area data. Materials
on left are test materials with M-1 scaffold treated samples indicated by (K) and S-1 indicated by
(B), and predicate materials, BioOss Collagen® (BOC) and Syntoss® (S), on right. Numerical
designation following letter code indicates study time point, either 1-month (1) or 2-month (2).
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Figure 4.8. Overview of IHC protocol. (Phase I) Paraffin-embedded tissue samples were
deparaffinized through xylene exposure followed by an ethanol rehydration gradient culminating in
samples being placed in tap water. An antigen retrieval step using pH 6 citrate buffer at 80-85℃
was used along with 1% triton in PBS solution at room temperature to expose antigens on tissue
surface for effective antibody binding. Prepped tissue was then blocked for endogenous hydrogen
peroxidase (HRP) to eliminate background. Primary antibodies (ᵒ1 Ab) for target protein were
applied to samples, which were then stored at 4℃ in a humid environment overnight. (Phase II)
Samples were washed and biotinylated secondary antibodies (ᵒ2 Ab) targeting IgG of the ᵒ1 Ab
host species were added. A streptavidin-HRP conjugate was then used to bind to biotin groups on
tissue surface. Nova Red or DAB kits utilizing a hydrogen peroxide containing stain were applied
and generated colorimetric reactions at the site of target proteins. A hematoxylin solution was used
to provide background contrast for protein stains and samples were run though a dehydration
process. Lastly, samples were mounted with a coverslip using limonene solution and imaged.
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Figure 4.9. IHC staining for OPN in M-1 (a-c) and S-1 (d-f) samples at 2 months after implantation.
Full defect region (a,d) derived from stitched 5x images and magnified regions of interest (b,c,f,e)
are shown.
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Figure 4.10. IHC staining for Sp7 in M-1 (a-c) and S-1 (d-f) samples at 2 months after implantation.
Full defect region (a,d) derived from stitched 5x images and magnified regions of interest (b,c,f,e)
are shown.
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Figure 4.11. IHC staining for CD34 in M-1 (a-c) and S-1 (d-f) samples at 2 months after
implantation. Full defect region (a,d) derived from stitched 5x images and magnified regions of
interest (b,c,f,e) are shown.
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Figure 4.12. IHC staining for FN in M-1 (a-c) and S-1 (d-f) samples at 2 months after implantation.
Full defect region (a,d) derived from stitched 5x images and magnified regions of interest (b,c,f,e)
are shown.

100

CHAPTER V:
IN VIVO ASSESSMENT OF ADVANCED OSTEOBIOLOGICS
PLATFORMS UTILIZING A RAT UNICORTICAL BONE DEFECT
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Abstract
The field of bone tissue engineering has seen extensive focus on the
development of novel and effective biomaterials that are capable of being applied
through minimally invasive methods. These materials offer the potential to treat
complex injuries while reducing major risk factors associated with surgical
implantation, namely infection. The application of such advanced material designs
will be largely dependent on the nature of the intended target defect. In this study
two advanced material designs were examined for their cyto/biocompatibility
characteristics. An expandable design, intended for applications that demand a
void-filling material capable of providing mechanical stability to surrounding tissue
through swelling pressure, was compared to a commonly used graft material,
BioOss Collagen®, while two iteration of an injectable design, which offer the ability
to stimulate accelerated or enhanced repair of fractures that can be stabilized
without surgical intervention, were assessed in relation to an allogenic particulate
graft material known as Veragraft®. The evaluated test articles maintained
compositional properties similar to previously examined graft designs, thereby
offering the promise of osteogiologic functional characteristics in addition to their
application methods. Implementation of these biomaterials in a rat unicortical tibial
defect demonstrated that the test articles were biocompatible and did not differ
significantly from commonly used predicate devices in the formation of early
collagen and bone structures within treated sites. Based on these findings, further
evaluation of these advanced graft technologies will be pursued to more accurately
determine their effectiveness as osteogenic platforms.

Introduction
As previously discussed, bone tissue is comprised of an intricate cellular
matrix with hard mineral and soft organic regions that vary in ratio and distribution
based on the type of bone and position within the structure. The complex and
dynamic nature of this tissue provides bone with a high capacity for regeneration
and reconstruction. However, despite this impressive natural reparative capacity,
a lack of effective treatment or immobilization of the fracture/defect site can lead
to abnormal growth following injury to tissue. For this reason, the use of graft
materials is a common practice in treatment of such injuries, as it permits and
promotes accelerated and improved repair. It has been demonstrated that the use
of bone grafts offers the potential to enhance anatomical and functional integrity of
the restored structure. The current gold standard for bone graft material,
autogenous bone, can increase the risk of a procedure for the individual due to
multiple surgical sites and potential for donor site morbidity. The focus of many
current research efforts therefore has been to develop effective and relatively
inexpensive graft designs capable of providing comparable results to autografts.
Effective material designs should therefore maintain osteobiologic characteristics,
namely osteo-conductive, osteo-inductive, and osseo-integrative potential (Hasan
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et al., 2018). These properties will determine the capacity of the graft material to
facilitate and promote bone growth, induce bone formation, and interact with
surrounding tissues respectively. A previously examined scaffold, denoted in the
previous chapters as S-1, and the modified fabrication method described in the
previous chapter, M-1, demonstrated promise as osteogenic platforms in both in
vitro and in vivo applications (Bow et al., 2019). To further explore the potential of
such graft materials and the potential to develop relatively advanced materials with
similar compositional elements, a comparative in vivo study was performed using
multiple experimental advanced materials alongside commercially available graft
materials to evaluate the biocompatibility and effectiveness of the test articles with
relation to predicate devices.
Masson’s trichrome and immunohistochemistry (IHC) assessment
techniques were utilized as the primary means to evaluate the treated tissues.
Trichrome imaging permitted evaluation of early collagen/bone surfaces within the
treated defect regions, while ICH allowed detection of key proteins in the tissue
associated with osteogenic and cell attachment functions, as well as their
distribution and organization. Bio-markers for IHC were selected with a focus on
examining proteins associated with osteogenesis, angiogenesis, and cellular
attachment. Those chosen to evaluate osteogenesis included osteopontin (OPN),
which is associated with early stages of bone development and osteoblastic
activity, and BMP-2, which is strongly correlated with prolific bone development
and mineralization. The cluster of differentiation (CD) markers CD34 and CD117
were used to assess the presence of progenitor cells as well as the ability of the
graft materials to stimulate angiogenesis. Furthermore, CD117 serves as an
indicator of the final stages of osteoblastic differentiation. Lastly, fibronectin (FN)
and collagen II markers were utilized to determine any morphological and
organization variations in the extracellular matrix architecture observed in the two
treatment groups.
Observational comparisons of these key proteins within defect regions for
test articles in relation to their respective predicate devices are anticipated to
demonstrate the potential of these advanced materials as osteobiologic grafts.
Furthermore, understanding of the handling techniques required for surgical
application of these materials will be essential for development of materials with
clinical translatability. Therefore, the primary objectives of the work described in
this chapter are to verify the cytocompatibility/biocompatibility of the materials and
detail the advantages and limitations of the current form of the test articles.

Advanced Materials
Super-hydratable Scaffold Design
A scaffold design comprised of nano-hydroxyapatite (nHA) and
decellularized bone particles (DBPs) within a super-hydratable polymeric matrix
was utilized as an osteogenic platform. The composite resembles the S-1 and M1 scaffolds examined in previous studies (Bow et al. 2019; Jackson et al. 2018) in
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compositional mineral additives, nHA and DBPs, yet employs a different
degradable polyurethane (dPU) with enhanced hydrophilicity. This material design
was designated as Expand-o-graft.
Increased swelling capacity due to
incorporation of this dPU enables this scaffold design to be delivered through
minimal invasive procedures, as relatively small material pieces are capable of
expanding to fill an entire defect. The proposed application would utilize a trocar
device to implement an appropriately sized scaffold within the target defect, at
which point absorption of in situ fluids were cause expansion of the material to
effectively fill the void space (Chen, Yuen, & Li). Despite the differences in
mechanical
properties
of
this
scaffold
iteration,
the
cytocompatibility/biocompatibility characteristics are expected to echo those of
previously assessed scaffold compositions, and therefore in vitro assessment for
this material iteration was limited to a brief DiI fluorescent labeling assay to verify
that cells are detected and proliferate within the matrix.
Injectable Scaffold Design
An injectable scaffold design was examined with two compositional
variants. The basal construct for these materials consists of a thermosensitive
polymer known as poloxamer 407 or Pluronic f127 solution at 30% weight by
volume, which is capable of gelling from liquid to solid form as it approaches body
temperature. Addition of nHA to this dynamic substrate provides the potential for
the matrix to facilitate bone formation, as nHA has demonstrated osteo-inductive
properties (Della Bella et al., 2018; Teng, Lee, Wang, Shin, & Kim, 2008), and
integration with the surrounding tissue. A variation on this composite includes
chitosan as an additive, which has demonstrated biocompatibility and potential as
a natural adhesive (Georgopoulou et al., 2018; Li, Zhang, & Zhang, 2018; Park et
al., 2009). These injectable material designs were designated as I-1 for the basal
construct with nHA additive and I-2 for the basal construct with both nHA and
chitosan additives. As the composites exist as low viscosity solutions at reduced
temperatures, the ability to load the bone graft material into standard syringes
therefore permits minimally invasive application to bone defects via hypodermic
needle targeting (Coeshott et al., 2004; Julie Westerink et al., 2001). The
substantial variations in material composition as compared to previously examined
scaffold designs mandated that a more rigorous in vitro assessment be conducted
to verify that the fabricated materials were non-cytotoxic prior to application in an
in vivo model.
Predicate Device Comparisons
For evaluation of the super hydratable scaffold, a commonly implemented
bone graft known as BioOss Collagen® was utilized. The composite consists of
DBPs of bovine origin suspended within a porcine collagen matrix and has a wealth
of literature describing its application in vivo (Miron et al., 2016; Sohn & Moon,
2018; Xu, Qi, Lin, Zhu, & He, 2019). The material is provided as a sterile block
that can be cut to size according to the target defect. Since this scaffold does not
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expand to the extent of the test article, it cannot be applied in the same minimally
invasive fashion and requires full exposure of the defect for implantation.
To assess the cytotoxicity, biocompatibility, and effective regenerative
capacity of the Pluronic f127-based composites a predicate device known as
VeraGraft® was implemented. The commercially available allogenic bone graft
product is produced and distributed by Avtec Surgical. The material is comprised
of demineralized cortico-cancellous bone of human origin and comes contained in
a sterile syringe for application. The size of the compositional particles (0.25-1.0
mm) prevent the deployment of the material through traditional syringe needle
sizes yet can be extruded readily through the standard syringe bore-size.
VeraGraft® dispenses as a thick putty consistency from its container, but upon
contact with fluid converts to a low-viscosity liquid mixed with the bio-active
particles (https://www.bonegrafting.com/veragraft-tm-en).

Advanced Material In Vitro Analysis
Caprine Mesenchymal Stem Cell Culture Parameters
To evaluate the cytocompatibility of the described advanced test articles it
was determined that naïve caprine mesenchymal stem cells (cMSCs) would offer
a more accurate representation of material effect as compared to the earlier
utilized MC 3T3-E1 cells (ATCC) since these commercially available cells are preosteoblastic in nature. Bone marrow derived cMSCs (bmcMSCs) were extracted
and isolated under an approved IACUC protocol and were expanded to generate
a bank of cells below passage 5. Cells were seeded in tissue culture polystyrenetreated flasks and cultured at 37°C and 5% CO2 in DMEM-F12 media with 10%
fetal bovine serum and 1% amphotericin penicillin streptomycin. Media was
replaced every 2–3 days, and the cells were passaged when they were
approximately 70-80% confluent. Confluent cells were exposed to 0.05% Trypsinethylenediaminetetraacetic acid solution for 2 minutes at 37°C and collected. Cells
were counted using a hemocytometer with Trypan Blue staining.
For viability and proliferation experiments to assess injectable material
designs, cells were seeded at 1000 cells per well to a 96-well tissue culture plate
and allowed to attach and proliferate for 24 hours. Injectable materials and their
comparative predicate device were then added while in liquid state and placed into
incubation conditions to cause gel formation. This process was conducted using
DiI stained cells for tracking morphology over time and unstained cells for CalceinAM staining and for MTS proliferation assessment.
For viability verification of cells on the super-hydratable scaffold design,
material pieces were placed in wells of a 96-well non-tissue culture plate. Cells
were then seeded to material samples at 1000 cells per well. Only DiI labeled cells
were used for this assessment and fluorescent signal was monitored for
morphological characteristics over time. As the primary function of this experiment
was to verify that cells behaved similarly to previous scaffold designs, this was the
sole in vitro assay conducted for this material design.
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Viability and Proliferation
Calcein-AM staining, coupled with the quantitation of fluorescent intensity,
was used to assess cell viability after exposure to materials, while MTS assay was
implemented to determine impact on proliferation. For Calcein-AM fluorescence
imaging cells were incubated in growth media for 7 days, at which point samples
were washed to remove materials and reveal cells for staining and subsequent
imaging. Cells were incubated with 0.1 mL of staining solution, containing 2 μg/ml
calcein-AM reconstituted with dimethyl sulfoxide, at 37°C for 5 minutes.
Fluorescent images of all samples were taken to verify the presence of cells and
their viability.
Proliferation assessment using MTS assay for material exposed cells was
conducted at 3, 7, and 9 days of culture growth. Briefly, MTS kit reagent (Promega)
was added directly to cell cultures resulting in a colorimetric reaction due to the
production of formazan crystals that is proportional to the density of the cell
population in the well. Therefore, an increase in absorbance readings at
subsequent time points would be indicative of healthy cellular proliferation.
Cell viability was confirmed on the I-1 and I-2 composites using Calcein-AM
staining over a period of 7 days (Figure 5.1). MTS readings over the described
time course revealed a relatively consistent absorbance value over the course of
the study (Figure 5.2). As cells were determined to be healthy through CalceinAM imaging, this plateauing of MTS values may indicate that, while the test articles
are non-cytotoxic, they may not be conducive to in vitro proliferation. This may
potentially be due to the materials obscuring surface area in the wells, which was
not impeded in cell monolayer controls and those exposed to the predicate device,
Veragraft®.
Lastly, DiI fluorescent monitoring for all test articles was conducted to verify
cytocompatibility prior to in vivo application. Fluorescence was detected in
samples cultured for 5 days furthering indicating that materials did not negatively
impact cell viability.

Advanced Material In Vivo Analysis
Tibial Defect Model
As described in an earlier chapter Sprague Dawley rats were received and
maintained at facilities for 7 days prior to surgeries for acclimation. Pre-surgical
analgesic application of buprenorphine was administered, and animals were
anesthetized with isoflurane delivered via inhalation for the duration of the surgery.
Sterile prep of the surgery site was performed through removal of hair and
application of 70% ethanol, chlorohexidine, and betadine solutions respectively.
Surgical operations were then carried out. Briefly, linear incisions were made
directly below the tibial stifle joints and muscle tissue was resected to expose the
tibal crests. Unicortical defects were then generated at 3mm in diameter in the
medial face of both tibias. Each resulting defect was filled with one test article,
either the Expand-o-graft, I-1, or I-2, and the contralateral defect was treated with
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that test article’s respective predicate device, BioOss Collagen® for expandable
scaffold and Veragraft® for injectables. As such, each animal permitted accurate
comparative assessment by addressing potential animal-to-animal variation in
implantation reaction. Following implantation, sites were closed through initial
suturing of muscle layer and then of subcutaneous tissue. Animals were monitored
closely to verify recovery and then transferred to housing room. Regular
monitoring of animals was then carried out for 1-month post-operation. At 1-month
post-operation animals were sacrificed as per protocol and CT scans of region of
interest were taken. Treated tibias were then harvested from specimens for
histological sectioning and staining, with tissue stored prior to sectioning in Decal
A solution.
Advanced Material Handling
Surgical handling of the Expand-o-graft test article was largely similar to
previously examined S-1 and M-1 scaffold designs; however, the expansion
capacity of the construct due to the super-hydratable nature was a crucial
consideration for in vivo application. Graft material was cut to approximately 2mm
x 2mm x 2mm pieces to accommodate for swelling after contact with blood at
defect site. Scaffolds were firmly placed within defects and allowed to undergo
initial expansion to ensure that the material was not protruding from injury. Similar
to previously assessed scaffolds, the Expand-o-graft maintained its structural
integrity after exposure to in situ fluid. As observed in the mandibular in vivo
assessment described in the previous chapter, the BioOss Collagen® scaffold,
which is readily commercially available and commonly implemented for dental
surgical applications, maintained its structural integrity when applied to the defects
and was conducive to cutting and shaping. Both test article and predicate device
proved easily manageable and convenient in surgical application.
The injectable test articles at first presented a unique challenge in prepping
for surgical implementation yet were demonstrated to readily be applicable using
a standard sterile syringe with 22.5-gauge needle. Bulk material sterilized through
UV-radiation was stored at low temperatures to ensure low viscosity before mixing
and drawing into sterile syringes. Needles were replaced with new sterile/capped
needles and material samples were stored in clean containers at 4℃. On the day
of surgery, materials syringes were placed on ice packs in an insulated container
until needed. After defect generation, I-1 or I-2 material syringes were removed
from cold chamber and 0.2cc of low viscosity was applied to site. The solutions
were observed to rapidly gel within the site and did not appear to be readily
disturbed when the muscle tissue was close above wound site. These injectable
materials therefore proved to be relatively easy to handle and show a promising
means for applying a scaffold with osteogenic components. Conversely, the
compared predicate device, Veragraft®, was relatively difficult to handle compared
to all other tested materials, as the original putty consistency bone particulate mix
liquified upon contact with in situ fluids.
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CT Analysis
CT scans were performed on animals after sacrificed at 1-month postoperation. 3D renders were generated and collected scans were evaluated by a
certified radiologist for both quantitative and qualitative parameters.
Measurements for area and density comprised the quantitative element and were
coupled with a set of qualitative characteristics developed and employed in a
previous study. These parameters include subjective rankings of 0 (negligible) to
3 (severe) for periosteal reaction, sclerosis, swelling, and mineralization, as well
as healing with scores ranging from 0 (no closure) to 3 (completely healed).
CT imaging verified that defect generation was successful, and graft
materials persist within the treated sites (Figures 5.3-5.4). Defects appeared to
have largely healed with mineralized tissue formation observed in defect sites
treated with the Expand-o-graft, BioOss Collagen®, and Veragraft® materials.
Those treated with I-1 and I-2 demonstrated smooth surfaced and largely healed
surfaces, which may in part have been due to spontaneous healing unimpeded by
presence of a scaffold within the defect.
Histological Analysis
Histological sections were cut from paraffin-embedded decalcified tissue
samples at 1-5um thickness. Sets of sections included one slide stained with H&E
for general cellular reaction assessment, one slide stained with Masson’s
Trichrome for evaluation of present tissue types, and 3-5 unstained slides for
immunohistochemistry (IHC). Masson’s Trichrome stained slides will be used to
generate semi-quantitative data for new early collagen/bone tissue surface area.
Captured images are processed through ImageJ software to create binary masks
highlighting tissue of interest, which can be subsequently measured as a ratio of
highlighted area to total area.
Gross evaluation of H&E stained sections showed an absence of
inflammatory signs indicating that all materials were biocompatible. Masson’s
Trichrome imaging resulted in observational differences in tissue content within the
defect (Figures 5.5-5.9), yet ImageJ software assessment yielded no significant
difference is the area of early collagen/bone structures between the Expand-ograft, I-1, or I-2 are their respective predicate device. Though not significant in
area coverage defects treated with all test articles appeared to demonstrate a
highly organized formation of these early collagen/bone tissue fronts within the
defect.
Immunohistochemistry Analysis
Unstained histological sections were subjected to deparaffinization and
prepped for immune-staining to determine presence and abundance of specific
proteins related to angiogenesis and bone formation. Prepped samples received
primary antibodies for the marker of interest, which were then subjected to a
biotinylated secondary antibody. A Nova Red kit utilizing horseradish peroxidase
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(HRP) was then applied to stain samples and permit visualization of tissue surface
proteins for image analysis.
Preliminary imaging of IHC stained sections showed promise in detecting
specific markers within sample tissue and were used to observationally assess the
distribution and organization of tissue surface proteins. Proteins associated with
osteogenesis, angiogenesis, and cellular attachment were examined. These
included the early-stage bone development marker OPN for early bone formation
fronts, markers CD117 for progenitor cells and early vascular formation, and both
collagen II and FN for cellular matrix organization within the defects (Figures 5.10).

Conclusion
The examined advanced materials demonstrated the unique ways in which
basal scaffold components that have shown certain regenerative capacities, in this
case osteogenic potential, can be implemented in relatively complex designs to
target specific diseases or injuries. As determined through both in vitro and in vivo
experimentation, the Expand-o-graft, I-1, and I-2 technologies all proved to be noncytotoxic and biocompatible. Furthermore, CT and histological evaluation
demonstrated that scaffold materials, with the exception of I-1 and I-2, maintain
residual particulate within the defect at 1-month post-implantation. Though the
injectable graft treated defects showed strong healing characteristics, this may in
part be due to spontaneous healing that was not impeded by the presence of a
solid graft material.
Both the super-hydratable and injectable graft designs were observed to
handle well in surgical application, with the Expand-o-graft being readily cut and
shaped to an appropriate size to accommodate swelling after fluid contact. I-1 and
I-2 technologies were capable of being drawn into and dispensed from standard
sterile syringes with a 22.5-gauge needle. Compared predicated devices were
more variable, with BioOss Collagen® being easily manageable but Veragraft®
displaying a liquifying characteristics upon contact with blood, which made this
graft material difficult to maintain at site.
Successful detection of key proteins associated with osteogenic and cell
attachment functions through IHC indicated that scaffold designs may also be
capable of stimulating osteogenic repair of the treated site. The comparable
intensity of the stain between defects treated with the Expand-o-graft and those
treated with BioOss Collagen® represents a promising regenerative capacity for
the test article design. Based on the compositional inclusion of nHA and chitosan
in the I-1 and I-2 injectable iterations, it is anticipated that these materials will also
demonstrate osteogenic potential; however, these analyses are still on-going.
The analytical techniques used to evaluate the in vitro and in vivo impact of
these various osteogenic scaffold technologies have thus far focused on visual
observations of biological systems, either through cell culture or harvested tissue,
after exposure of that system to the material of interest. However, these methods
do not offer a means of ascertaining the molecular mechanisms involved in
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stimulating and promoting the observe effects. To address this this following
chapter will utilize a multi-omics approach to determine potential pathway
mechanisms impacted by exposure of naïve human cells to the previously
discussed S-1 scaffold.
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Appendix

Figure 5.1. Calcein-AM imaging of bmcMSCs exposed and unexposed to injectable materials and
corresponding predicate device. Uptake of staining agent is indicative of cell viability. I-1 (d) and
I-2 (b) exposed cells were compared with Veragraft® predicate device (c) exposed cells and
unexposed cell monolayers (a).
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Figure 5.2. MTS proliferative assay for bmcMSCs seeded to injectable scaffold designs.
Absorbance readings taken at day 3, 7, and 9 of culture growth were plotted to determine changes
in cell density for I-1 and I-2 test articles as compared with predicate device and cell monolayer
controls. Samples were run in triplicate.

114

Figure 5.3. CT 3D renders (a,b) and cross-sectional images (c,d) for expandable design treated
tibial defects. Expand-o-graft treated (a,c) and BioOss Collagen® treated defects (b,d) are shown.
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Figure 5.4. CT 3D renders (a-c) and cross-sectional images (d-f) for injectable design treated tibial
defects. Veragraft® (a,d), I-1 (b,e), and I-2 (c,f) treated defects (b,d) are shown.
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Figure 5.5. Masson’s Trichrome Images of BioOss Collagen® treated defect. 5x magnification
stitched composite image of tibia is shown (a) with magnified regions of interest within the defect
boundary (b-d).
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Figure 5.6. Masson’s Trichrome images of Expand-o-graft treated defect. 5x magnification
stitched composite image of tibia is shown (a) with magnified regions of interest within the defect
boundary (b-d).
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Figure 5.7. Masson’s Trichrome images of Veragraft® treated defect. 5x magnification stitched
composite image of tibia is shown (a) with magnified regions of interest within the defect boundary
(b-d).
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Figure 5.8. Masson’s Trichrome images of I-1 treated defect. 5x magnification stitched composite
image of tibia is shown (a) with magnified regions of interest within the defect boundary (b-d).
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Figure 5.9. Masson’s Trichrome images of I-2 treated defect. 5x magnification stitched composite
image of tibia is shown (a) with magnified regions of interest within the defect boundary (b-d).
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Figure 5.10. IHC imaging for Expand-o-graft treated tibial defects. 10x imaging of fibronectin (a),
CD117 (b), collagen II (c), and osteopontin (d) staining within defect center.
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CHAPTER VI:
MULTI-OMICS ASSESSMENT OF MOLECULAR MECHANISMS
ASSOCIATED WITH ADHESION AND OSTEOGENIC FUNCTIONS
OF HUMAN MESENCHYMAL STEM CELLS EXPOSED TO AN
OSTEOBIOLOGIC PLATFORM
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Abstract
The highly dynamic nature of bone represents one of the most impressive
natural reparative tissue mechanisms, exhibiting constant remodeling through
osteoblastic and osteoclastic activity in response to mechanical forces and injuries.
However, it is precisely the complexity of this system that results in difficulties in
developing effective grafting biomaterials for bone injuries that exceed the
regenerative capacity of native bone. As the current gold standard, autologous
tissue grafts, poses restrictive features including limited source materials and
donor site morbidity, the design of easily synthesizable materials that facilitate
repair comparable to autografts is essential. As previously reported, we have
fabricated a multilayered nanocomposite comprised of polyurethane (PU) and
nano-hydroxyapatite (nHA) films interspersed with decellularized bone particles
(DBPs) for bone regeneration and have demonstrated it to be cytocompatible with
murine osteoblasts in vitro and biocompatible, with osteobiologic characteristics,
in vivo. To evaluate the underlying mechanisms of this biomaterial, the in vitro
behavior of human fat-derived mesenchymal stem cells seeded onto these
scaffolds was assessed using a combinatorial approach of transcriptomic and
metabolomic analyses. Expression data from osteogenic and signal transduction
gene arrays and small molecule concentrations, measured via liquid
chromatography-mass spectrometry, were cross-examined using Integrated
Molecular Pathway Level Analysis (IMPaLA), Database for Annotation,
Visualization, and Integrated Discovery (DAVID), and ConsensusPathDB (CPDB)
online tools to generate a fundamental collection of scaffold-influenced pathways.
Results demonstrated up-regulation of key osteogenic, cellular adhesion, and cell
signaling markers, and interactions between bone morphogenic protein (BMP),
Hedgehog (HH), and Wnt signaling pathways were determined to be primary
candidates for the osteobiologic mechanisms of the scaffold design. The detection
of complimentary metabolites, such as ascorbate, further indicate that scaffolds
generate intricate cellular environments, promoting cell attachment and
subsequent osteo-differentiation. These data contribute to the understanding of
cell recruitment, adhesion, and subsequent osteogenic signaling in the presence
of this 3D nanocomposite scaffold.
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Introduction
As discussed in previous chapters, the field of bone tissue engineering
faces unique challenges in biomaterial design stemming largely from the highly
dynamic nature of the target tissue, which boasts impressive natural reparative
mechanics. Native bone undergoes continuous remodeling through osteoblastic
and osteoclastic activity in order to accommodate for mechanical forces exerted
on the body and provide structural support. For this reason, non-compromised
bone tissue, as opposed to that observed in osteoporotic or geriatric individuals, is
innately capable of repairing sizable injuries. However, for cases of tissue damage
that result in defect sizes that exceed the reparative capacities of native bone, or
for accelerated repair, the application of a graft material is necessary (Majidinia,
Sadeghpour, & Yousefi, 2018). Currently the gold standard for such graft material
is the use of autologous tissue, as this eliminates concerns of immunogenic
reaction and provides an optimal substrate for cellular on-growth and eventual
integration. Despite the superior reparative and restorative functions of autografts,
implementation incurs an increased risk to patient due to the need for multiple
surgical sites and donor site morbidity, as well as a reliance on a limited source
material (Garcia-Gareta, Coathup, & Blunn, 2015). Therefore, the development
and characterization of graft materials with similar or enhanced functionality and
biocompatibility to autografts offer an attractive alternative (Araujo et al., 2019;
Bow et al., 2019; Garcia-Gareta et al., 2015).
Scaffold constructs being designed for bone tissue engineering must
display key osteobiologic characteristics including osteo-inductive, osteoconductive, and osseo-integrative functions in order to facilitate effective repair of
native tissue (Agrawal & Ray, 2001; Albrektsson & Johansson, 2001; Gao, Peng,
Feng, & Shuai, 2017; Hasan et al., 2018). Osteo-induction indicates that the
material is capable of stimulating exposed cells toward an osteogenic lineage
(Garcia-Gareta et al., 2015). The osteo-conductivity of a material determines the
ability of cellular communication across and through a substrate (Garcia-Gareta et
al., 2015). Lastly, osseo-integration indicates the measure of cell migration and
subsequent formation of mature bone tissue on the surface and throughout the
matrix.
We have previously reported the fabrication of a nanocomposite,
designated as S-1, comprised of nano-hydroxyapatite (nHA)/polyurethane (PU)
film layers with interspersing layers of decellularized bovine bone particles (DBPs),
which demonstrated biocompatibility and osteobiologic characteristics, both in vitro
and in vivo (Bow et al., 2019; Jackson et al., 2018). Specifically, 8-week old
Sprague Dawley rats had a significant increase in new bone formation over a 30day period within unicortical tibial bone defects when treated with the
nanocomposite. Based on these results, we next wanted to elucidate more precise
mechanisms by which exposed cells are influenced. To accomplish this, a multiomics approach utilizing analytical tools of transcriptomics and metabolomics was
implemented (Araujo et al., 2019).
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The use of various molecular analytical tools to assess the functions of
biomaterials is an expanding and promising approach as the critical attributes of
bone scaffolds previously described depend heavily on the cell-biomaterial
interactions (Gao et al., 2017). Stimuli from surface topography or composition
elements can drastically alter the influence of a material on exposed cells, leading
to substantially different results both in vitro and in vivo (Jackson et al., 2018).
Transcriptomics, the study of mRNA molecules and functional impact of their
expression levels, offers the potential to observe the fundamental regulative
capacities of cells through comparative assessment of gene expression (Ullah,
Sittinger, & Ringe, 2013). The extraction and analysis of messenger RNA (mRNA)
from cells exposed to various conditions, through generation of complimentary
DNA (cDNA) and subsequent real-time polymerase chain reaction (qPCR), offers
the potential to evaluate the effect of specific treatments on exposed cells by
normalizing to an untreated control culture. Such methods have been utilized in
studies focused on elucidating correlations between discrete material
characteristics and biological responses of exposed cells in attempts to establish
pathway libraries. These data can be used as a rationale to design biomaterials
with specific topographies, architecture, and composition (Araujo et al., 2019).
Transcriptomic evaluation is further strengthened through supplementation
with metabolomic data, which consists of small molecule concentrations often
detected through mass spectrometry (Schrimpe-Rutledge, Codreanu, Sherrod, &
McLean, 2016). Metabolites and their associated relative abundance can be
detected in a wide variety of samples ranging from acellular materials to tissue
biopsy samples, providing the potential for comparative analyses based on
metabolite profiles. By cross-examining detected small molecules with expression
data for up-regulated and down-regulated genes respectively, it is possible to
develop a basic pathway(s) to describe the behavior of cells on scaffolds. Online
databases, such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) and
Reactome, and tools for assessing connective elements within data sets, including
Integrated Molecular Pathway Level Analysis (IMPaLA), Database for Annotation,
Visualization, and Integrated Discovery (DAVID), and ConsensusPathDB (DPDB),
can be used to generate basic pathway maps demonstrating the signals that are
triggered when cells interact with scaffolds.
The use of naïve cells during in vitro examination of scaffold mechanisms
provides a more relevant model, as pre-differentiated and immortalized cell lines
may demonstrate expression profiles that reflect innate cell programming instead
of material induced effects. Naïve cells alleviate this concern and permit accurate
assessment of material impact on cellular activity. Furthermore, the use of human
mesenchymal cells (MSCs) contributes a clinical translatability aspect, as the
designed scaffold technology is intended for human medicine. Therefore, studies
conducted to elucidate mechanisms of the biomaterial were facilitated using
mesenchymal stem cells (MSCs) derived from human adipose tissue. MSCs are
naïve, multi-potent cells with the potential to differentiate toward multiple lineages,
namely osteocytes, chondrocytes, and adipocytes (Alghazali et al., 2017). These
126

cells therefore offer a unique potential as a reparative element, especially when
coupled with a scaffold substrate, and have been implemented in a wide array of
cell-based treatments (Majidinia et al., 2018). Seeding of these adipose-derived
human MSCs (adhMSCs) onto the nanocomposite scaffold can thereby evaluate
the effectiveness of the construct as an osteogenic platform capable of application
as a cell-based therapy device (Majidinia et al., 2018). Our objective in the present
study, based on data from previous studies, is to assess the interaction between
human MSCs and the nanocomposite through variations in both the transcriptional
and metabolite landscapes. Expression of genes associated with osteogenesis,
cellular attachment, and signaling were examined for hMSC seeded
nanocomposites and compared with hMSCs differentiated through a wellestablished method to assess scaffold impact. These data were then crossexamined with small molecule concentrations to elucidate potential candidate
pathways of effect for the scaffold on exposed cells.

Human Mesenchymal Stem Cell In Vitro Work
Human Mesenchymal Stem Cell Isolation and Expansion
Adipose-derived human MSCs (adhMSCs) were collected and primary
cultures were established using previously described methods (Alghazali et al.,
2017). The stromal vascular fraction of cells which contain the non-hematopoietic
mesenchymal stem cells were seeded in DMEM-F12 growth media containing
10% fetal bovine serum and 1% amphotericin penicillin streptomycin and
expanded in vitro in tissue culture polystyrene flasks. Cells incubated at 37°C and
5% CO2 , with growth media replaced every 2-3 days, were enzymatically released
from substrates with 0.05% Trypsin-EDTA upon reaching approximately 80%
confluency and then allocated to tissue culture flasks for continued expansion,
cryopreservation, or experimental set-ups.
Cells were characterized and
confirmed to be mesenchymal stem cells using previously described in vitro assays
including tri-lineage differentiation (Alghazali et al., 2017).
Viability and Proliferation
1mm x 5mm x 5mm pieces of the nanocomposite scaffold material (Bow et
al., 2019) were cut from bulk scaffold blocks to ensure that each piece fit into a
single well of a 24 well plate. Each scaffold piece was placed into individual wells
of a non-tissue culture plate and cell solutions were directly added to ensure
cellular migration into nanocomposite pores through capillary action. Cells were
seeded at a density of 4x104 cells/scaffold for proliferation assessment and 5x105
cells/scaffold for both gene expression and small molecule analyses. As
previously observed, total RNA from cell/scaffold complexes at 5 days that had
received media with osteogenic-inducing agents (growth media supplemented with
10mM beta glycerophosphate, 10nM dexamethasone, 100nM ascorbic acid)
showed consistently poor yields (Bow et al., 2019). This indicated that stress
factors due to conditions may negatively impact cell health, which was observed
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in previous studies (Bow et al., 2019). As such, cell seeded scaffolds were
exposed to growth media lacking osteo-differentiation additives. Media was
refreshed every 2-3 days.
Quantitative analysis of Calcein-AM fluorescent staining was performed as
previously described (Jackson et al., 2018) to determine cellular proliferation and
viability on the scaffolds. Briefly, cell-seeded scaffolds were cultured in blackwalled 24-well plates, preventing light refraction across wells during reading, and
assessed in triplicate at 3, 5, and 7 days of growth. Samples were incubated in
0.5 mL staining solution, containing 2 μg/ml calcein-AM dimethyl sulfoxide mix in
HBSS, at 37 °C for 5 minutes. Fluorescence intensity was quantitated using a
plate reader set-up with an excitation wavelength of 485 nm and an emission
wavelength of 528 nm. Normalized average fluorescent intensity values from each
time point were plotted to generate a cellular proliferation curve.
Calcein-AM staining demonstrated an increased fluorescent intensity in
cell-seeded scaffolds at day 7 that was significantly greater than days 3 and 5
(Figure 6.1). This increase over time indicates that scaffolds are cytocompatible.
Cytocompatibility
Cell adhesion and morphology on 3D scaffolds was assessed in vitro using
previously described methods (Bow et al., 2019). Visualization of changes in cell
morphology was performed using the fluorescent cytoplasmic stain, DiI. Cells
seeded on scaffolds were compared to polystyrene tissue-culture dish controls,
with cell-void scaffolds in media acting as negative controls.
In vitro evaluation of DiI stained cells demonstrated that cells adhered to the
3D scaffolds and exhibited clustering dynamics within 5-7 days of seeding,
suggesting osteogenic differentiation (Figure 6.2). Cell behavior was similar to
our observations on 2D PU/nHA films as described earlier (Jackson et al., 2018).
Cells adhered and formed clusters on the 3D scaffolds within 5 days of seeding
and in the absence of any differentiating reagents (dexamethasone, beta
glycerophosphate and ascorbic acid). Monitoring of cellular morphology and
proliferation through fluorescent microscopy demonstrated cell adhesion and
supports cytocompatibility of the materials. Additionally, as described earlier, the
mineral components of the scaffolds prevented the use of alizarin red and alkaline
phosphatase staining, to demonstrate osteogenesis. Hence, morphological
observations and analysis of gene expression were used for in vitro evaluation of
scaffolds.

Transcriptomics
PCR Profiler Microarrays
Total RNA was extracted from the cell/scaffold constructs 5 days post
seeding as described previously (Bow et al., 2019) and was analyzed for the
expression of genes relating to osteogenesis and signal transduction (Ullah et al.,
2013).
Total RNA isolation was performed with Trizol extraction agent
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(ThermoFisher) as per the manufacturer’s protocol with modifications to increase
the yield of RNA (Lee et al., 2018). cDNA was prepared using a Qiagen First
Strand cDNA reverse transcription kit (Qiagen). A housekeeping RT 2 Profiler array
(Qiagen) was used to ensure that the quality of isolated RNA.
Expression was then evaluated using Qiagen RT2 Profiler arrays for human
osteogenesis (PAHS-026Z) and signal transduction (PAHS-014Z) with 2ug of total
RNA per array with approximately 20.8ng cDNA per PCR reaction, with samples
run in triplicate.

Data Correlation
Relative fold differences in the gene expression and corresponding
significance values were generated through Qiagen data center
(https://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-centeroverview-page/). Expression of cells seeded on scaffold constructs for 5 days was
compared to cell monolayers differentiated on polystyrene substrates for 21 days
with osteo-differentiation media (Jackson et al., 2018).
Established techniques using cells cultured for 21 days with osteodifferentiation media were used as a positive control to assess cells seeded onto
scaffolds and cultured for 5 days. RNA expression was compared using PCR
evaluation of RNA, extracted and isolated from these cell cultures, and was carried
out utilizing Qiagen RT2 Profiler arrays for human osteogenesis and signal
transduction pathways. Resulting expression fold changes and significance data
between genes for samples were generated through Qiagen data center
(https://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-centeroverview-page/). Fold change values and representative heatmaps for each array
type are presented in Figure 6.3. Significantly upregulated genes, as designated
by Qiagen Data Center output for genes with expression fold differences greater
than 2, and their associated functions can be viewed in Tables 6.1-6.4. Notably,
expression of RUNX2, an essential gene in regulating bone formation and
remodeling, did not significantly differ from cell controls stimulated through wellcharacterized differentiation agents toward osteo-lineage. Furthermore, data from
signal transduction arrays showed enhanced expression of genes related to
oxidative stress, Notch, Hedgehog (HH), and hypoxia signaling pathways.

Metabolomics
LC-MS Analysis
Metabolite relative abundance profiles for cells exposed to scaffolds were
compared with cell- and material-based controls to determine variations among
groups. hMSCs seeded on material scaffolds for 5 days were compared to cell
monolayers cultured on polystyrene substrates with and without osteodifferentiation media additives to evaluate concentration differences associated
with the examined nanocomposite. Additionally, acellular scaffold samples both
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exposed and not exposed to growth media were implemented to address
metabolites attributed to the basal scaffold or media additives. Samples, in
triplicate, were collected by scaping wells, adding HBSS, and pelleting suspended
samples. Pellets were isolated and weighed before storage at -80ᵒC with cell
monolayer, dry material blanks, media-exposed material blanks, and cell-seeded
material samples having weight ranges of 16.53-25.64mgs, 30.14-50.37mgs,
92.08-175.82mgs, and 165.30-191.71mgs respectively. Once all the samples were
collected, the metabolites were extracted using a 20:40:40 solution of
water/methanol/ acetonitrile with 0.1M formic acid following the procedure
previously reported Lu, W. et al. 2008. Samples were sent to the Biological and
Small Molecule Mass Spectrometry Core and the Department of Chemistry at the
university of Tennessee, Knoxville for processing. Samples were reconstituted in
ultrapure water and then ran on a liquid chromatography-mass spectrometer (LCMS); they were separated on a Phenomonex Synergi Hydro RP column (100 mm
x 2.0mm, 2.5 µm pore size, Phenomonex, Torrance, CA) using ultra high-pressure
liquid chromatography. The mobile phases used to elute the metabolites were A)
97:3 water/methanol with 11mM tributyl amine and 15 mM acetic acid; and B)
methanol. The 26-minute gradient, adapted from Lu, W. et al. 2010, was used with
a flow rate of 0.2 mL/min. The gradient was as follows: 0 minutes, 0% B; 5 minutes,
20% B; 13 minutes, 55% B; 15.5 minutes, 95% B; 19 minutes, 0% B; 25 minutes,
0% B. The Exactive Plus Oribtrap Mass Spectrometer (Thermo Fisher Scientific,
Waltham, MA) operated in negative mode with an electrospray ionization (ESI)
probe; the scan range was set from 72 to 1,200 m/z while resolution was set to
140,000; the capillary temperature was set to 300 °C. Once the raw files were
obtained from the MS, the files were converted to mzML using an open source file
converter. The mzML files were loaded into Metabolomic Analysis and
Visualization Engine (MAVEN) where metabolites were chosen based on peak
shape and signal-to-noise ratio. Metabolite intensities were recorded and
normalized to sample weight.
Metabolite Data Analysis
Formatted data was uploaded to Metaboanalyst, an online metabolomic
statistical analysis tool, to evaluate statistically significant variations among
samples groups and generate visual representative figures. Partial least squares
discriminant analysis (PLS-DA) performed on samples groups demonstrates
similarity of within groups and significance between groups. Post-analysis heat
maps offer a visual representation of metabolite variation that drive group
differences in PLS-DA plot. Literature sources and KEGG database were then
used to correlate detected metabolites and relative concentrations to potential
metabolic pathways.
Assessment of small molecule abundance profiles utilizing sparse partial
least squares discriminant analysis (sPLS-DA) showed that all samples groups
were discrete and unique, with intra-group samples forming tight clusters. When
comparing all study groups, it was determined that 18 metabolites were
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significantly responsible for driving the separation of sample groups; however,
separation of study groups into cell-oriented, hMSC monolayers with and with
osteo-differentiation media addititves, and material-oriented, acellular scaffolds
exposed and unexposed to growth media, sub-sets permitted more relevant
comparisons due to initial sample characteristics, primarily weight and culture size.
Sub-set groups both maintained the hMSC-seeded scaffold samples. Though
groups remained discrete and unique when examined with sPLS-DA, it was
observed that the metabolites responsible for the distinct grouping varied in both
number and significance with 21 metabolites for cell-oriented and 15 metabolites
for material-oriented samples (Figures 6.4-6.5). Generation of corresponding
heatmaps for cell-oriented and material-oriented groups was performed by
normalizing
hMSC-seeded
scaffolds
to
sub-group-specific
controls,
undifferentiated hMSC monolayers and acellular scafflds unexposed to growth
media (Figure 6.6). The resulting heatmaps were assessed for metabolites of
interest (MoIs), metabolites that may serve as corollary links to cellular and
material mechanisms. For cell-oriented sub-set groups, comparisons in which
both cell monolayers exposed to differentiation agents and cells seeded to
scaffolds exhibited higher concentration than control samples, as well as those in
which cell-seeded scaffolds alone displayed superior concentration, were selected
as MoIs. The first of these relations being potentially indicative of an osteodifferentiation-related metabolite, and the second representing a scaffold-related
metabolite. Similarly, MoIs from material-oriented sub-set groups were selected if
a metabolite concentration was significantly different in cell-seeded scaffold
samples compared to one or both control groups to examine changes due to
cellular activity on constructs. Metabolites that demonstrated an increase in
concentration in scaffold samples exposed to media as compared to dry scaffold
samples were considered to be associated with components of media and were
therefore not further examined.

Fundamental Pathway Development
Pathway Correlation Databases
Evaluation of molecular impact of the scaffold material on exposed cells
was conducted through use of both IMPaLA (http://impala.molgen.mpg.de/) and
the DAVID (https://david.ncifcrf.gov/) online software tools, with gene and
metabolite inputs entered using Entrez IDs and KEGG IDs respectively.
For IMPaLA assessment, the detected metabolites were cross-examined
with the up-regulated genes identified in osteogenic and signal transduction arrays.
The generated list of pathways consists of pathway names, database source for
pathway information, target genes involved in pathway, and target metabolites
involved in pathway. Manual selection was performed to develop a discrete
collection of pathways of interest (PoIs). PoIs containing greater numbers of target
genes/metabolites were considered to be more relevance to material impact.
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DAVID assessment was then performed for pathway enrichment based on
functional categories, gene ontology, pathways, protein domains, and tissue
expression characteristics based on the default statistical parameters (Dennis et
al., 2003; Huang, Sherman, & Lempicki, 2008). Resulting PoIs are then divided
into clusters based on pathway enrichment significance.
PoI collections generated through IMPaLA software can be observed in
Table 6.5. Highly ranked PoIs for samples were largely associated with metabolic
and signaling functions, including extracellular matrix organization and cell
differentiation pathways. PoIs selected from clusters lists, created utilizing DAVID,
are displayed in Table 6.6 with pathway enrichment score, number of overlapping
genes, and significance values. These generated PoIs demonstrate significant
impact on bone mineralization, osteoblast differentiation, and osteoclast
differentiation, which supports the osteogenic potential of the scaffold.
Furthermore, cell signaling pathways, such as BMP signaling and cell-cell junction
organization, compliment IMPaLA output and suggest that scaffolds facilitate
cellular attachment and communication in addition to osteobiologic functions.
Network Mapping Software
Visualization of pathway connections for both gene and metabolite
elements were facilitated through the use of CPDB (http://cpdb.molgen.mpg.de/).
Network map construction using CPDB was used to illustrate intra-omic connection
based on gene expression and metabolite concentration data respectively.
Observational assessment of intra-omic networks for gene expression and
metabolite concentration data individually through CPDB demonstrated elements
associated with osteogenic and cellular attachment functions (Figures 6.7-6.8).
As in IMPaLA and DAVID assessments, CPDB generated for transcriptomic and
metabolomic data demonstrate pathways closely associated with osteogenesis
and cellular attachment. Mapped transcriptomic data (Figure 6.7) include
pathways for cell differentiation, BMP signaling, and osteoclast differentiation, as
well as extracellular matrix organization and focal adhesion pathways, and is
reinforced by detection of fundamental metabolism functions and mineral
absorption pathways through small molecule assessment with CPDB (Figure 6.8).

Conclusion
As expected, based on previous in vitro and in vivo studies, the 3D nanocomposite
scaffold comprised of nHA/PU films interspersed with layers of DBPs, was
cytocompatible with human adipose-derived MSCs. To elucidate the underlying
mechanisms of this material, a combinatorial approach of transcriptomics and
metabolomics was utilized. The scaffold demonstrated significant up-regulation of
genes closely associated with osteogenesis and indicated that a combined
interaction of multiple pathways may be responsible for the osteobiologic
characteristics exhibited by the material (Figure 6.9). Specifically, the interaction
of Hedgehog, Wnt, and BMP signaling pathways appear to play a crucial role in
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stimulating exposed cells (Li et al., 2015). Members of the BMP family have been
strongly correlated with osteogenesis and mineralization, in particular BMP2/4/6/7, though recruitment of Smad 1/5/8, which interacts with Smad 4 to regulate
gene expression. Up-regulation of BMP-2/4/6/7, BMP receptors, and Smad 1/4/5
may therefore provide evidence for activation of this pathway (Beederman et al.,
2013; Wang et al., 2014). Additionally, coordination of this BMP signaling with
both Wnt and Hedgehog signaling pathways are indicated by increased expression
of essential pathway elements including PTCH1, Gli1, and Wnt5A (James et al.,
2012). Hedgehog, as well as Notch, signaling mechanisms have been previously
demonstrated to have vital roles in bone remodeling and development through
modulation of osteoblast and osteoclast activity (Regan & Long, 2013; Yang,
Andre, Ye, & Yang, 2015). The described pathways culminate in up-regulation of
vital transcription factors, RUNX2 and Sp7, shown to elicit pro-osteogenic and antiadipogenic characteristics (Chi, Liu, Xing, & Tian, 2016; James, 2013). This
results in the enhanced production of key proteins for OB differentiation and
ossification, including SPP1 and BGLAP (Hishida, Nishizuka, Osada, & Imagawa,
2009), both of which were up-regulated. As the expression of RUNX2 is similar
between material-seeded cells and osteo-differentiated cultures, expression
difference in other osteo-related targets may represent the mechanisms by which
scaffold induces exposed cells toward an osteogenic lineage in 5 days.
Furthermore, hypoxia signaling and oxidative stress may also play important roles
in facilitating the osteo-inductive capacity of the scaffold, as these have been linked
to skeletal development and bone promoting functions. Hypoxia signaling has
been shown to have a role in the formation of endochondral bone, as well as the
potential to modulate bone formation through manipulation of oxygen sensing
(Yellowley & Genetos, 2019); while oxidative stress, relating to an imbalance
between generated radical oxygen species (ROS) and available counteracting
antioxidants, has demonstrated substantial influence on bone remodeling
functions through suppression of osteoblast activity, temporarily reducing
mineralization capacity and promoting resorption dynamics (Domazetovic,
Marcucci, Iantomasi, Brandi, & Vincenzini, 2017). These data combined with the
up-regulation of genes associated with cellular attachment functions, including
cell-cell and cell-extracellular matrix (ECM) adhesion/communication
mechanisms, indicate that scaffold constructs facilitate cellular infiltration,
attachment, and proliferation with subsequent stimulation of osteogenesis.
By correlating the transcriptomic data with detected metabolite
concentrations in cell-seeded scaffolds, fundamental pathways were constructed
that appear to further support the function of scaffolds as osteogenic platforms.
Particularly the detection of ascorbate, a small molecule strongly associated with
osteogenesis, in scaffold samples at markedly lower concentrations than those in
scaffold blanks may indicate utilization of the metabolite by seeded cells. Xanthine
concentration levels detected in cell-seeded scaffolds may also correlate to
upregulation of oxidative stress pathway genes. Importantly, overlay of multi-omic
data through IMPaLA software revealed that overlapping regions between gene
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expression and metabolite concentrations were related to primarily cellular
metabolism and signaling functions, which demonstrates that scaffolds are
capable of facilitating cell-cell communication and supporting intricate intrastructural cell networks.
As expected, the results of this study demonstrate that the scaffold material
is both biocompatible and maintains osteogenic properties. Evaluation of the
transcriptional landscape for scaffold exposed hMSCs as compared with cells
differentiated on polystyrene further indicated this osteogenic potential in the upregulation of expression in genes strongly associated with pro-osteogenic and cell
attachment functions. Fundamental pathway analysis of expression data revealed
interactions among BMP, HH, and Wnt signaling mechanism as primary
candidates for the osteobiologic characteristics of the material. Among these, HH
appears to play a particularly crucial role, and thus will be the target of future
studies, which will implement HH-specific PCR profiler arrays (Qiagen) and
inhibition assays to elucidate precise mechanisms.
The pro-osteogenic potential of the scaffold indicates that it may serve as
an effective scaffold for both long and flat bone injuries, as it is capable of
facilitating cellular in-growth and subsequent ossification. Further evaluation of
scaffolds as delivery vehicles for drug and cell-based treatments are expected to
yield enhanced osteobiologic graft treatments. Furthermore, application of similar
experimental approaches for tissue samples from in vivo analyses of this material
may provide invaluable insight as to its impact on native tissue, which is essential
for translation to clinical applications.
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Appendix

Figure 6.1. Calcein-AM proliferation assay conducted at day 3, 5, and 7 time points. Fluorescent
intensity measurements output by plate reader are normalized to blank scaffold readings. The
significant increase in fluorescence intensity between day 7 readings and previous time points is
indicates by asterisks.
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Figure 6.2. DiI fluorescent images of cells seeded to scaffolds at day 3 and 7 time points.
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Figure 6.3. Heatmap (a,c) and gene primer layout with expression values (b,d) generated from
human osteogenesis (a-b) and signal transduction arrays (c-d). Heatmaps utilize a Log2 scale and
represent expression fold changes in cell-seeded materials relative to differentiated cell
monolayers. Complimentary gene primer lists display numerical expression fold change values for
heatmaps with associated rankings shown directly below values. Rankings are assigned via
Qiagen Data Center processing and indicate the quality of the expression relationship based on
cycle threshold (Ct) values of PCR runs. Primary attention was given to unranked and rank “A”
genes, as these were most reliable values.
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Table 6.1. List of up-regulated genes associated with human skeletal development, categorized
by function.
Function

Gene

Fold Relation

ACVR1

6.8474

BGLAP

10.0949

BMP2

1508.4894

BMP3

80.3869

Function
Cartilage
Condensation

Osteoclast
Differentiation

Gene

Fold Relation

BMPR1B

8.8697

COL2A1

99.1968

SOX9

63.5090

BGLAP

10.0949

BMP4

11.7579

TNF

49.0287

BMP6

4.0527

TNFSF11

118.7861

BMPR1A

4.4760

ACVR1

6.8474

BMPR1B

8.8697

BGLAP

10.0949

BMPR2

2.1222

BMP2

1508.4894

CHRD

101.2812

BMP4

11.75.79

COL2A1

99.1968

BMP6

4.0527

EGFR

2.9599

BMPR1A

4.4760

FGF2

4.7422

BMPR1B

8.8697

FGFR2

4.8643

BMPR2

2.1222

GDF10

4.0247

CHRD

101.2812

Ossification

Osteoblast
Differentiation

GLI1

20.0967

FGF2

4.7422

IGF1R

5.3848

FGFR2

4.8643

MMP2

31.3898

GDF10

4.0247

MMP8

24.7992

GLI1

20.0967

MMP9

131.8014

NOG

3.2465

NOG

3.2465

SMAD1

2.7363

SMAD1

2.7363

SMAD3

11.2789

SMAD3

11.2789

SP7

91.7025

SOX9

63.5090

SPP1

18.8813

SP7

91.7025

TWIST1

5.4474

SPP1

18.8813

ALPL

3.3688

TGFB1

13.6632

FGFR1

14.8826

TGFB2

2.1819

TGFBR1

5.8383

TNFSF11

118.7861

TWIST1

5.4474

Other Skeletal
Development
Genes
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Table 6.2. List of up-regulated genes associated with human bone mineral metabolism,
categorized by function.
Function

Bone Mineralization

Gene

Fold Relation

ACVR1

6.8474

BGLAP

10.0949

BMP2

1508.4894

BMP4

11.7579

BMP6

4.0527

BMPR1A

4.476

BMPR1B

8.8697

BMPR2

2.1222

FGFR2

4.8643

SMAD3

11.2789

SOX9

63.509

TGFB1

13.6632

TWIST1

5.4474

BGLAP

10.0949

CALCR

12.8073

EGF

37.0711

FGF2

4.7422

MMP2

31.3898

Calcium Ion Binding & Homeostasis
MMP8

24.7992

TGFB1

13.6632

VDR

2.0217
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Table 6.3. List of up-regulated genes associated with human cell adhesion molecules, categorized
by function.
Function

Cell-Cell Adhesion

Cell-ECM Adhesion

Other Cell Adhesion Molecules

Gene

Fold Relation

BMPR1B

8.8697

COL14A1

5.4348

COL2A1

99.1968

EGFR

2.9599

ICAM1

4.4042

SOX9

63.5090

TGFB1

13.6632

TNF

49.0287

TNFSF11

118.7861

CD36

3.8519

COL2A1

99.1968

ITGA2

42.0944

ITGAM

29.4233

SMAD3

11.2789

BGLAP

10.0949

COL15A1

6.2285

TNF

49.0287
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Table 6.4. List of up-regulated genes from associated with human signal transduction pathways,
categorize by function.
Function

Hedgehog
Signaling

Gene

Fold Relation

BCL2

42.7478

BMP2

802.1775

BMP4

6.2670

PTCH1

23.3353

Function
TGFβ Signaling

Gene

Fold Relation

IFRD1

4.8605

MYC

4.9398

FOSL1

7.0508

CCND2

2.2519

WNT Signaling
WNT1

178.2524

MMP7

3.1335

WNT2B

2.7090

MYC

4.9398

WNT3A

127.5080

BCL2A1

137.9286

WNT5A

2.3205

BIRC3

3.6921

WNT6

254.4276

CCL5

8.9039

FTH1

5.3435

ICAM1

2.1452

GCLC

2.5867

IFNG

119.5202

GCLM

16.3866

TNF

68.9643

GSR

3.1191

HES1

4.0309

HMOX1

778.4413

HES5

149.8918

SQSTM1

47.6513

HEY1

8.3462

NFκB

Oxidative Stress

Hypoxia
Signaling

TXN

2.3583

HEY2

63.9015

TXNRD1

4.4417

HEYL

78.672

CA9

39.6096

LFNG

13.7794

NOTCH1

12.1631

EPO

76.8751

HMOX1

778.4413

SLC2A1

2.1852

VEGFA

2.1452

Notch Signaling
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Figure 6.4. sPLS-DA plot and driving metabolites for cell-based group. sPLS-DA plot (a)
demonstrating discrete cluster separation for metabolomic concentration assessment of cell-based
subset group with differentiated (green) and undifferentiated (blue) hMSCs on tissue culture
substrates compared to hMSC-seeded (red) scaffolds. 21 metabolites driving separation (b)
observed in sPLS-DA plot.
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Figure 6.5. sPLS-DA plot and driving metabolites for material-based group. sPLS-DA plot (a)
demonstrating discrete cluster separation for metabolomic concentration assessment of materialbased subset group with dry (red) and media-exposed (green) scaffolds compared to hMSCseeded (blue) scaffolds. 15 metabolites driving separation (b) observed in sPLS-DA plot.
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Figure 6.6. Heatmaps depicting metabolite abundance variations. Metabolite abundance
variations among both cell-based (a), with differentiated (green) and undifferentiated (blue) hMSCs
on tissue culture substrates compared to hMSC-seeded (red) scaffolds, and material-based (b)
sub-set groups, with dry (red) and media-exposed (green) scaffolds compared to hMSC-seeded
(blue) scaffolds. Log scale used for relative abundance is Log2.
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Table 6.5. Pathways of interest list generated using IMPaLA software. Pathways are listed based
on number of overlapping elements, both up-regulated genes and detected metabolite, in
descending order. Source information for pathways is derived from KEGG, Reactome, and
Wikipathways databases.
Pathway Name

Signal Transduction

Signaling by Receptor Tyrosine Kinases
Signaling by TGF-beta Family Members
Extracellular Matrix Organization
Gene Expression (Transcription)
Generic Transcription Pathway

Overlapping Genes
TGFB1; BMP2; BMPR2; IGF1R; NOG;
EGF; CALCR; PDGFA; EGFR; SPP1;
NFκB; ITGA2; MMP9; BMPR1A; SMAD1;
SMAD2; SMAD3; SMAD4; SMAD5;
VEGFA; VEGFB
PDGFA; EGFR; EGF; SPP1; FLT1;
VEGFA; IGF1R; ITGA2; MMP9; VEGFB
TGFB1; BMP2; SMAD2; BMPR1A;
BMPR2; SMAD1; NOG; SMAD3; SMAD4;
SMAD5
TGFB1; COL2A1; PDGFA; ITGAM; SPP1;
BMP2; BMP4; ICAM1; ITGA2; MMP9
TGFB1; EGFR; BMP2; SMAD3; SMAD1;
SMAD2; BGLAP; SMAD4; SP7; VEGFA
TGFB1; EGFR; BMP2; SMAD3; SMAD1;
SMAD2; BGLAP; SMAD4; SP7; VEGFA

Overlapping Metabolites
N-Acetylglucosamine; UDP-NAcetylglucosamine; Dopamine; NAD+;
Glutamate
NAD+
NAD+
Ascorbate
Glutathione Disulfide; Glutathione;
Ascorbate; Glutamate; NAD+
Glutathione Disulfide; Glutathione;
Glutamate; NAD+
Glucose 1-phosphate; Asparagine; Valine;
Glutamate; NAD+; Inosine; NAcetylglucosamine; UDP-NAcetylglucosamine
N-Acetylglucosamine; UDP-NAcetylglucosamine; Glucose 1-phosphate;
NAD+; Glutamate

Metabolism of Proteins

TGFB1; SPP1; BMP4; SMAD3: SMAD1;
SMAD2; BGLAP; SMAD4; ALPL

Post-translational Protein Modification

TGFB1; SPP1; BMP4; SMAD3: SMAD1;
SMAD2; BGLAP; SMAD4; ALPL

Differentiation Pathway

TGFB1; PDGFA; BMP4; EGF; TNFSF11;
NOG; VEGFA

Ascorbate

HIF-1 Signaling Pathway

EGFR; FLT1; EGF; NFκB; IGF1R; VEGFA

Ascorbate

Developmental Biology

SMAD3; ITGA2; SMAD4; EGFR; SMAD2

Glutamate

MAPK Family Signaling Cascades

PDGFA; EGFR; EGF

Glutamate

MAPK1/MAPK3 Signaling

PDGFA; EGFR; EGF

Glutamate

RAF/MAP Kinase Cascade

PDGFA; EGFR; EGF

Glutamate

Vitamin B12 Metabolism

NFκB; ICAM1

Ascorbate; NAD+; Creatinine

Signaling by NOTCH

EGFR; EGF

N-Acetylglucosamine; UDP-NAcetylglucosamine

Collagen Formation

COL2A1; MMP9

Ascorbate

Signaling by GPCR

EGFR; CALCR

Dopamine; NAD+; Glutamate

GPCR Downstream Signaling

EGFR; CALCR

Dopamine; Glutamate; NAD+

Cellular Responses to External Stimuli

NFκB

Glutathione Disulfide; Glutathione; NAD+

Cellular Responses to Stress

NFκB

Glutathione Disulfide; Glutathione; NAD+

cAMP Signaling Pathway

NFκB

Dopamine

Collagen Biosynthesis and Modifying
Enzymes

COL2A1

Ascorbate

Protein Digestion and Absorption

COL2A1

Asparagine; Valine; Glutamate
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Table 6.6. Pathways of interest list generated using DAVID software for up-regulated genes from
osteogenesis and signal transduction arrays. Pathways and associated overlapping genes and
significance values are displayed. Benjamini scores represent a statistical correction of p-values
to minimize false discovery rate.
Pathway

Overlapping Genes

p-value

Benjamini

TGF-beta Signaling Pathway

18

1.10E-17

1.60E-15

Cellular Response to BMP Stimulus

11

2.80E-16

1.20E-13

Positive Regulation of Pathway-restricted SMAD Protein
Phosphorylation

12

9.30E-16

2.70E-13

BMP Signaling Pathway

13

5.40E-15

1.10E-12

Signaling Pathways Regulating Pluripotency of Stem Cells

18

9.10E-14

4.30E-12

Positive Regulation of Bone Metabolism

9

9.50E-12

1.00E-09

Positive Regulation of Osteoblast Differentiation

10

2.60E-11

2.30E-09

Extracellular Space

41

2.80E-22

4.10E-20

SMAD Protein Signal Transduction

12

2.00E-11

2.80E-12

Negative Regulation of Canonical Wnt Signaling Pathway

5

1.10E-02

9.70E-02

Growth Factor

14

1.40E-14

7.50E-13

Osteogenesis

5

1.90E-05

2.20E-04

Positive Regulation of Ossification

4

3.10E-05

6.20E-04

Osteoclast Differentiation

10

1.20E-05

1.20E-04

FOxO Signaling Pathway

10

1.50E-05

1.30E-04

Adherens Junction

7

1.20E-04

7.20E-04

Cell-cell Junction Organization

3

4.00E-03

4.10E-02

Angiogenesis

11

2.80E-07

9.00E-06
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Figure 6.7. ConsensusPathDB network map generated from up-regulated osteogenesis and
signal transduction array expression data. Pathway elements were selected from generated list
based on significance (p-value<0.01) and relevance to utilized arrays. Pathway connective
elements were filtered for at least a 0.15 overlap and 2 overlapping agents.
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Figure 6.8. ConsensusPathDB network map generated from metabolite abundance data.
Pathway elements were selected from overview based on significance (p-value<0.01).
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Figure 6.9. Osteogenic signal pathway interaction schematic. Pathways for BMP, HH, and Wnt
signaling are shown with up-regulated genes highlighted in yellow and the similarly expressed
Runx2 in green. a.) BMP ligands bind with BMP receptor subunits stimulating Smad 1/5/8 to couple
with Smad 4. b.) HH binding to PTCH1 surface protein prevents inhibition of SMO, permitting
production of Gli2/3 and subsequent transcription of Gli1 and Hip1. c.) Wnt interacting with Fz
surface protein leads to release and subsequent accumulation of β-Cantenin, which then couples
with TCF/LEF and CBP-p300. a-c.) BMP, HH, and Wnt pathways culminate in up-regulation of
crucial osteogenic transcription factors including Runx2 and Sp7. d.) Naïve MSCs are stimulated
via matrix proteins toward osteo-lineage and differentiate to osteoprogenitor cells expressing
primary cell attachment proteins including collagen 1 (Col1) and fibronectin (FN). e.) Induction of
osteoprogenitor cells by osteo-related transcription factors results in early maturation stages for
osteoblastic (OB) cells promoting proliferation and expression of alkaline phosphatase protein
(ALP). Late-stage development of OB cells show increased expression of osteocalcin (BGLAP)
and osteonectin (ON) proteins. f.) Mature OBs demonstrate reduced proliferative characteristics
and enhanced expression of osteopontin (SPP1) protein. Matrix mineralization through OB activity
during differentiation toward osteocytes results in bone mass formation.
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CHAPTER VII:
CONCLUSIONS AND FUTURE DIRECTION
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Introduction
The work comprised in these chapters represents the extensive research
conducted to examine the biological impact of a novel osteobiologic graft and its
various iterations. A vital first step in this process was the development of basic
cell culture work practices, which would lay the foundation for many of the crucial
experimental steps to come. Initial work with MC 3T3-E1 cells provide invaluable
experience and served as the basis for future work with multiple naïve primary cell
lines. Observations of these immortalized cells also worked to establish a
morphological baseline for cell monolayers on tissue-treated polystyrene surfaces
prior to test element exposure. As shown in Figure 7.1, cell seeding density
experiments were performed to assess the optimal density for cell controls in future
experiments, comparing cell monolayers to material-seeded cells. This evaluation
was comprised of morphological and proliferative assessment techniques using
Calcein-AM staining and an MTS assays kit respectively.
Introduction of the early-stage iterations of the graft fabricated and provided
by the collaborative research team at the University of Arkansas at Little Rock
(UALR), polyurethane (PU) films impregnated with varying percentages of nanohydroxyapatite (nHA), was conducted to determine which films should be utilized
in the 3D scaffold fabrication process. The selection of superior film ratios was
dependent on the morphology and proliferative characteristics of material-seeded
cells as compared with monolayer controls. This was done to ensure that the
selected material was non-cytotoxic and did not prevent cell proliferation.
Additionally, attention was given to any perceived evidence of potential osteogenic
effects exhibited on material-seeded cells, as the compositional inclusion of nHA
was anticipated to imbue the material with an osteo-inductive capacity.
Unfortunately, both the PU and nHA components interfered substantially with the
MTS proliferation assay and osteogenic potential assay, Alizarin Red staining,
respectively. The results of the MTS assay were determined unreliable based on
observed healthy cell populations on films, apart from the 60/40 PU-nHA film,
through Calcein-AM and DiI fluorescent imaging in spite of the contradictive low
MTS absorbance values, which would appear to indicate low cell population
numbers and potential cell death. It was postulated that the formazan crystals
produced in reaction to the MTS reagent, which are responsible of the measured
colorimetric intensity, were in some way trapped within the polymeric matrix
preventing release into media and subsequent analysis. Similarly, the Alizarin Red
staining assay, commonly used to determine if a material or additive has an
osteogenic impact on cells, was rendered ineffectual by the nHA content of the
films. As this stain targets mineralized regions by binding to calcium within the
extracellular matrix, the presence of a calcium phosphate (CaP) rich mineral in the
material resulted in extensive background staining that completely obscured
assessment of the seeded cells. The intensity of this background staining was
associated with the percentage of incorporated nHA in a given film with increased
compositional nHA resulting in more prolific sample staining (Figure 7.2). To
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circumvent these challenges, a Calcein-AM fluorescent assay (Crisan et al., 2015)
was conducted to verify viability and track proliferation characteristics for materialseeded films, while a morphometric assessment was performed using a DiI
fluorescent marker to track the development of nodules that correlated to
mineralized clusters observed in films without nHA content. The results of these
studies, discussed in Chapter II, indicated that two of the film iterations, the 80/20
and 90/10 PU-nHA compositions, were promising candidates for fabricating a
multi-layered osteobiologic platform, as both film iterations displayed
cytocompatibility and did not impede cell growth/proliferation. Furthermore, these
iterations appeared to demonstrate some osteo-inductive characteristics,
particularly the 80/20 material.
After selection of candidate films, multi-layered scaffold designs based on
each film were fabricated as described in Chapter III, with 80/20-derived scaffolds
designated as S-1 and 90/10-derived scaffolds as S-2. A cursory in vitro
examination of the scaffolds was conducted to verify that the final compositions,
which now included decellularized bone particles (DBPs), maintained
cytocompatibility. This was done by imaging of DiI labeled cells seeded to
constructs and demonstrated cells were capable of migrating in materials and
proliferating, though clarity of imaging suffered due to challenges associated with
intra-scaffold imaging for largely opaque 3D structures. Additionally, RNA was
isolated from cell-seeded material samples to evaluate expression of a couple key
osteogenic genes, which demonstrated expression of both the early bone marker
osteopontin (OPN) and the mineralization marker osteocalcin (OCN). This
indicated that both scaffolds maintained osteogenic capacities, particularly in the
case of the S-1 iteration. The process of extracting and isolating total RNA from
these scaffolds again provided challenges due to material composition. As
described in an article by Lee et al. (Lee, 2011), the presence of CaP materials
during RNA extraction can complicate the procedure due to binding and trapping
of RNA by CaP particles. Therefore, a modified extraction method was utilized in
which the phenolic agent Trizol (Thermo Fisher Scientific) is added in two stages,
the first being for the initial extraction from the material and the second directly
following sonication. This method resulted in substantial improvements to both
yield and purity of isolated RNA and used for all future RNA extractions dealing
with these scaffold designs.
Following these in vitro assessments, the materials were then further
examined in vivo using a rat unicortical tibial bone defect to observe the effects of
the materials in a complex biological environment. One of the generated defects
at 3mm in diameter were treated with one of the material iterations, while the
contralateral limb defect was left untreated for control. At one-month postimplantation animals were sacrificed, CTs were performed, and samples were
collected for histology. Based on the results of both CT and histological
assessments, it was determined that both scaffolds were biocompatible and
maintained osteobiologic properties. Notably, the S-1 iteration appeared to
demonstrate enhanced osteogenic functions as compared to its sister scaffold, as
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evident in the significant levels of new bone formation over control samples. As a
whole the described unicortical tibial defect model proved sufficient for
biocompatibility assessment, yet comprehensive assessment of osteobiologic
characteristics such as osseo-integration and tissue in-growth were difficult to
discern, essentially given that the controls for this study appeared to undergo
spontaneous healing over the timeframe. Therefore, an alternative model
implementing a truly critically-sized defect was determined necessary to assess
accurately the function of this graft design in repair and restoration of bone tissue.
The S-1 scaffold, being isolated as the primary candidate for futures
evaluation, was subsequently examined in a comparative study alongside a
modified version of itself and two common applied predicated devices. The
modified version, designated as M-1, implemented an alternative fabrication
method. Both scaffolds, as discussed in Chapter IV, were applied to a criticallysize bone defect in rats. A 5mm diameter defect generated in the mandible these
rats were filled with one of four graft materials, either S-1, M-1, BioOss Collagen®,
or Syntoss®. These animals were then sacrificed at 1- and 2-month timepoints,
with CTs performed and samples then extracted for histology. Maintained
biocompatibility of both test articles was confirmed, and a significant level of early
collagen/bone formation was observed via Masson’s Trichrome staining
assessment in M-1 indicated that this modified variant of S-1 may offer superior
attributes for an osteobiologic platform. Immunohistochemistry (IHC) of tissue
sections further supported this potential, as key proteins for osteogenic and cell
attachment functions were observed throughout scaffold treated defects. These
proteins including OPN, Sp7, CD34, and fibronectin (FN), illustrated the capacity
of the scaffold designs to facilitate tissue ingrowth, promote osteogenic activity,
and stimulate extracellular matrix development throughout the defect. Conversely,
Syntoss® treated defects appeared to only demonstrate healthy integration with
native tissue at the material boundaries, while the scaffold interior showed poor
cellular activity. Similarities in performance of the test articles with samples treated
with BioOss Collagen® proved promising due to this predicate device’s
documented effectiveness in treating bony defects (Miron et al., 2016; Sohn &
Moon, 2018; Xu, Qi, Lin, Zhu, & He, 2019). As compared with the unicortical tibial
defect study, the mandibular defect model appeared to offer a more
comprehensive means of assessing the effectiveness of scaffold designs. The
consistent boundaries and critical-size of the defects allowed to ease of evaluating
attributes such as osseo-integration with the native tissue and tissue in-growth to
graft matrix. Furthermore, the application of IHC in samples from this model
proved an efficient method of comparing both protein expression and
organization/distribution throughout the defect region.
The fabrication of multiple advanced bone tissue engineering materials by
the UALR research team presented an interesting challenge, and the unicortical
tibial defect was again utilized as the primary purpose of the study was to
determine if the novel osteobiologic platforms were biocompatible. Additionally,
attributes of the two material designs made them inherently unsuitable for the
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earlier described mandibular model. The advanced material designs, as discussed
in Chapter V, were divided into an iteration of the earlier S-1 and M-1 scaffolds that
employed a super-hydratable PU, which allowed for dramatic material swelling on
contact with material, and two iterations of an injectable scaffold based on a
thermosensitive polymer known as Pluronic f-127. A brief in vitro assessment of
these materials to verify that they were non-cytotoxic was performed and
demonstrated that materials were suitable for in vivo application. While the
expandable design, designated as Expand-o-graft, was able to be cut and sized
as previous scaffolds in the surgical theater, the enhanced swelling characteristics
demanded that the scaffold size be appropriately reduced as compared with the
3mm bore defect to prevent protrusion of the material from the defect or damage
to surrounding bone due to mechanical pressure. The thermosensitive injectable
materials, designated as I-1 for the iteration containing the basal construct with
nHA additive and I-2 for the iteration with this composition plus a quaternized
chitosan additive, was drawn into standard 1cc syringes with a 22.5-gauge needle
at low temperature and then UZ-irradiated to sterilize. These material aliquots
were then kept cold in surgical theater until needed. The injected material within
the defect site was observed to gel rapidly and maintained position largely during
closure of muscle layer. Both material designs, the expandable and injectable,
were observed to be biocompatible and did not differ significantly from compared
predicates, BioOss Collagen® and Veragraft® respectively, in CT or histological
data.
These osteobiologic platforms demonstrate advanced methods of
application that focus on the ability to implement graft technologies through
minimally invasive techniques, and therefore demand further examination for
determining osteogenic potential.
The observed osteogenic effects of the earlier iterations of the osteobiologic
platform, S-1 from Chapters 3-4, piqued interest in elucidating the potential
molecular mechanisms involved. As discussed in Chapter VI, a multi-omics
approach was utilized to determine candidate pathways induced by scaffold
exposure to naïve cells. Transcriptomics using gene arrays acquired from Qiagen
was combined with the ever-growing field of metabolomics to generate gene
expression and metabolite abundance profiles for naïve cells seeded to scaffolds
and cell monolayers that had been exposed to osteo-differentiation agents. A
comparison of these profiles utilizing available online databases and pathway
mapping tools then permitted the selection of pathways of interest for future
examination. Specifically, the interactions of the bone morphogenic protein (BMP),
Wnt, and Hedgehog (HH) pathways appeared to be primary candidates for
continued studies. Furthermore, the availability of HH-specific gene expression
profiler arrays by Qiagen offers an attractive opportunity to verify this pathways
significance in the scaffolds osteogenic influence on naïve cells. This assessment
of molecular mechanisms associated with these osteobiologic grafts will constitute
an intensive process but will elucidate invaluable information for graft technologies
intended for application in human medicine.
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Future Research
The ever-expanding field of biomaterial research and design affords a
wealth of opportunities to both develop and improve on existing technologies.
Within the field of bone tissue engineering alone are a vast number of graft designs
utilizing varying source material and demonstrating substantially differing levels of
effectiveness for repair and restoration of tissue. The application of material
constructs that resemble bone in structure or chemical make-up have been
attractive alternatives to the use of autologous grafts, due to heightened risk to
patients. However, these graft technologies are largely ineffectual for treating or
preventing injuries caused by diseases such as osteoporosis, in which bone tissue
becomes brittle and relatively fragile due to upregulated osteoclastic activity and
propensity of naïve cells to mature toward adipocytes as opposed to osteocytes.
These complex systems require more advanced approaches, as graft materials
applied to fractures in these conditions may be capable of facilitating integration
with native tissue or promoting new bone development. For this reason, graft
designs for such challenges may likely require the inclusion of stimulatory
elements such as protein or gene therapy approaches.
Of particular interest based on my previous studies with the earlier
discussed biomaterials, is the incorporation of an injectable matrix capable of then
stimulating surrounding tissue to produce therapeutic levels of a given protein or
proteins. Exploration into literature surrounding the application of chemicallymodified RNAs (cmRNAs) or modified-mRNAs (mmRNAs) appears to offer a
promising means for such stimulation of native tissue (Badieyan et al., 2016;
Badieyan & Evans, 2019; Balmayor et al., 2016; Balmayor et al., 2017; Evans,
2012). However, extensive research will be required to determine the optimal
combination of material and coded proteins to elicit the desired rescue of tissue
subject to these systemic diseases such as osteoporosis and may offer more rapid
potential in coupling with current scaffold designs for enhanced guided bone
regeneration. As this method may alleviate the complications associated with
adding supra-natural doses of exogenous protein to scaffold designs, this would
be a means of fabricating highly effective osteobiologics.

Conclusion
As discussed earlier, the work comprised in this document (Figure 7.3)
represents an extensive process for assessing the biological impact of an
osteobiologic technology, and steps through the stages associated with in vitro and
in vivo characterization of cyto/biocompatibility and osteogenic capacity.
Research efforts to examine the molecular mechanisms responsible for observed
osteogenic effects of the studied grafts are on-going and studies hold invaluable
information for the development of materials in the field of bone tissue engineering.
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Appendix

Figure 7.1. Early in vitro MC 3T3-E1 cell seeding density optimization. Morphological and
proliferative assessment of varying densities of MC 3T3-E1 on tissue-treated polystyrene surfaces
to determine optimal seeding density for future experiments. Calcein-AM staining of 20,000 cells
(a) and 60,000 cells (b) per well of a 24-well tissue culture plate were examined using an MTS
proliferation assay (c) in which the control comprised of empty plate wells.
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Figure 7.2. nHA content interference with Alizarin Red staining. Deep red staining of nHA content
of the films can be observed and background intensity was related to the percentage of nHA within
matrices as evident in observations of 60/40 (a), 70/30 (b), 80/20 (c), and 90/10 (a) PU-nHA
compositions.
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Figure 7.3. Research workflow overview. In vitro and in vivo experimental set-up and objectives
are plotted along research timeline to demonstrate general progression of studies.
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